NEWBORN SCREENING PROGRAM

ALASKA

PRACTITIONER’S MANUAL

NORTHWEST REGIONAL

NEWBORN SCREENING PROGRAM
ALASKA

State of Alaska
Division of Health Care Services

Thalia Wood, MPH

Christy LeBlond, MS

Oregon Health & Science University

Judith M. Tuerck, RN, MS

Robert D. Steiner, MD

Stephen L. LaFranchi, MD

Gregory Thomas, MD

Oregon Department of Human Services

Michael R. Skeels, PhD, MPH

Cheryl A. Hermerath, MBA, RM (NRM)

Leanne Rien, RN

# TABLE OF CONTENTS

MEDICAL PROGRAM FOLLOW-UP ................................................................................................ 1
LABORATORY AND FOLLOW UP TEAM ..................................................................................... 2
INTRODUCTION ............................................................................................................................. 3
DISORDERS COVERED BY THE PROGRAM .............................................................................. 4
TABLE I Summary of disorders screened by the program .......................................................... 4
TABLE II Normal values and criteria for requesting repeat samples ......................................... 7

ENDOCRINE DISORDERS .............................................................................................................. 9
  Congenital Adrenal Hyperplasia ............................................................................................... 9
  Congenital Hypothyroidism ..................................................................................................... 10

SICKLE CELL DISEASE AND OTHER HEMOGLOBINOPATHIES .............................................. 12

METABOLIC DISORDERS .......................................................................................................... 15
  Biotinidase Deficiency ........................................................................................................... 15
  Galactosemia .......................................................................................................................... 16
  Amino Acid Disorders .......................................................................................................... 18
  Organic Acidemias ............................................................................................................... 26
  Fatty Acid Disorders .......................................................................................................... 29

SCREENING PRACTICES ........................................................................................................... 32
  Definition .............................................................................................................................. 32
  Who is responsible for ensuring that the screen test is performed? ................................... 32
  Parental refusal to have baby tested .................................................................................... 32
  Proper time for testing ......................................................................................................... 32
  Testing before discharge ...................................................................................................... 32
  Testing before transfer of infant to another unit ................................................................. 33
  Patient demographic information ....................................................................................... 33
  Special considerations .......................................................................................................... 33
  Premature or sick infants ..................................................................................................... 33
  Hyperalimentation and antibiotic therapy .......................................................................... 33
  Transfusions .......................................................................................................................... 33
  Clinical signs of family history ............................................................................................ 34
  Specimen collection ............................................................................................................. 35
  Recommendation for heel puncture site in newborns ......................................................... 35
  Unsatisfactory specimens ..................................................................................................... 36
TABLE OF CONTENTS (continued)

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>REPORTING OF RESULTS</td>
<td>37</td>
</tr>
<tr>
<td>Practitioner responsibilities for documentation</td>
<td>37</td>
</tr>
<tr>
<td>Normal results</td>
<td>37</td>
</tr>
<tr>
<td>“Significant” abnormal results</td>
<td>37</td>
</tr>
<tr>
<td>“Other abnormal and repeats”</td>
<td>30</td>
</tr>
<tr>
<td>PROBLEMS IN SCREENING PRACTICES</td>
<td>38</td>
</tr>
<tr>
<td>Infants who are never tested</td>
<td>38</td>
</tr>
<tr>
<td>Parents’ refusal to have the baby tested</td>
<td>38</td>
</tr>
<tr>
<td>Common misconceptions</td>
<td>38</td>
</tr>
<tr>
<td>Timing of the tests</td>
<td>38</td>
</tr>
<tr>
<td>Specimen inadequacy</td>
<td>38</td>
</tr>
<tr>
<td>Inadequate demographic information</td>
<td>38</td>
</tr>
<tr>
<td>Problems related to specimen transport to the laboratory</td>
<td>38</td>
</tr>
<tr>
<td>EDUCATIONAL SERVICES</td>
<td>39</td>
</tr>
<tr>
<td>Screen practice surveillance program</td>
<td>39</td>
</tr>
<tr>
<td>Birth facilities, health departments and community practitioners</td>
<td>39</td>
</tr>
<tr>
<td>Parents and lay public</td>
<td>39</td>
</tr>
<tr>
<td>SCREENING KIT INFORMATION</td>
<td>40</td>
</tr>
<tr>
<td>Type of kits</td>
<td>40</td>
</tr>
<tr>
<td>Cost</td>
<td>40</td>
</tr>
<tr>
<td>Cost of diagnostic tests for confirmation of abnormal screening results</td>
<td>40</td>
</tr>
<tr>
<td>EXEMPTIONS</td>
<td>41</td>
</tr>
<tr>
<td>Fees</td>
<td>41</td>
</tr>
<tr>
<td>Religious exemptions</td>
<td>41</td>
</tr>
<tr>
<td>Parental refusal (Informed Dissent form)</td>
<td>42</td>
</tr>
<tr>
<td>REPORTING REQUIREMENTS</td>
<td>43</td>
</tr>
<tr>
<td>LIST OF LIVE BIRTHS</td>
<td>44</td>
</tr>
<tr>
<td>ALASKA STATUTE AND REGULATIONS</td>
<td>45</td>
</tr>
</tbody>
</table>

Acknowledgment: We are indebted to the Screening Coordinators in each of the regional states for their assistance and advice and to Leanne Rien, RN for many hours dedicated to this manual.
MEDICAL PROGRAM FOLLOW-UP
ALASKA

Medical consultants are available to provide consultation for the follow-up, evaluation and long-term management of children detected in this program. Questions concerning medical aspects of the program should be directed as below:

Metabolic Consultants: Robert Steiner, MD
(PKU, MSUD, biotinidase, galactosemia, other disorders detected as abnormal amino acid or acylcarnitine profile)
Cary Harding, MD
David Koeller, MD
Departments of Pediatrics & Molecular and Medical Genetics
Oregon Health & Science University, CDRC-F
3181 SW Sam Jackson Park Road
Portland OR 97201
503-494-7859 • (paging 503-494-8311) • FAX 503-494-2781
email: steinerr@ohsu.edu
hardingc@ohsu.edu
koellerd@ohsu.edu

Treatment and management of metabolic conditions is provided through the Alaska Metabolic and Genetic Clinic.
C. Ronald Scott, MD
University of Washington
Pediatric Genetics RD-20
PO Box 356320
Seattle, WA 98195
(206) 543-3370
mail: crscott@u.washington.edu

Cristine Trahms, MS, RD
University of Washington
PO Box 357920
Seattle, WA 98185-7920
(206) 685-1364
email: ctrahms@u.washington.edu

Endocrinology Consultants: Stephen LaFranchi, MD
(hypothyroidism, congenital adrenal hyperplasia)
Cheryl Hanna, MD
Bruce Boston, MD
Dan Marks, MD PhD
Department of Pediatrics
Oregon Health & Science University
3181 SW Sam Jackson Park Road
Portland OR 97201
503-494-1927 • FAX 503-494-1933
email: lafranchs@ohsu.edu

Hemoglobinopathy Consultant: Gregory Thomas, MD
(sickle cell disease)
Department of Pediatrics
Oregon Health & Science University
3181 SW Sam Jackson Park Road
Portland OR 97201
503-494-8716 • FAX 503-494-2721
email: thomasgr@ohsu.edu
LABORATORY AND FOLLOW-UP TEAM

State of Alaska
Team:

Thalia Wood, MPH, CLS
Newborn Screening Program Manager
Christy LeBlond, MS
Genetics Counselor
Division of Health Care Services
3601 C Street, Suite 934
Anchorage, Alaska 99524
907-269-3400 • FAX 907-269-3465
email: thalia_wood@health.state.ak.us
email: christy_leblond@health.state.ak.us

Newborn Screening
Education Coordinators:

Judith Tuerck, RN, MS
Sandra A. Banta-Wright, RNC, MN, NMP
Oregon Health Science University
Child Development and Rehabilitation Center
707 SW Gaines Road
Portland OR 97201
503-494-2776 • FAX 503-494-2781
email: tuerckj@ohsu.edu
bantawrs@ohsu.edu

Screening Laboratory
Consultants:

Michael R. Skeels, PhD, MPH
Laboratory Director
Oregon State Public Health Laboratories
1717 SW 10th Avenue
Portland OR 97201
503-229-5882 • FAX 503-229-5682
email: michael.r.skeels@state.or.us

Cheryl Hermerath, MBA, RM (NRM)
Newborn Screening Section Manager
Oregon State Public Health Laboratories
1717 SW 10th Avenue
Portland OR 97201
503-229-6576 • FAX 503-229-5682
email: cheryl.a.hermerath@state.or.us

Leanne Rien, RN
Newborn Screening Nurse Coordinator
Oregon state Public Health Laboratories
1717 SW 10th Avenue
Portland, OR 97201
503-229-5466 • FAX 503-229-5682
email: leanne.c.rien@state.or.us
INTRODUCTION

The disorders covered by the screening program are rare, collectively affecting about 1 in 2,000 infants, so the chance that any single infant will be affected is remote. The cost of not diagnosing one of these conditions, both in human suffering and financial terms, is immense, because early diagnosis and treatment can result in normal growth and development. Babies with these conditions appear normal at birth. It is only with time that the biochemical abnormality affects the baby's health and development. By the time clinical symptoms appear, the damage may be permanent.

The goal of the Northwest Regional Newborn Screening Program (NWRNSP) which includes Oregon, Idaho, Nevada, Alaska and Hawai‘i is to identify all affected infants before damage can occur. To do so, every baby must be screened. This requires coordinated efforts from three groups of health care providers:

PRACTITIONERS: Responsible for the collection and handling of screening specimens, for providing parents with correct and current information and for prompt follow-up in the event of an abnormal result.

CENTRAL SCREENING LABORATORY: Responsible for testing, record keeping, quality control of laboratory methods, notification of results and tracking of abnormal and unresolved results.

TREATMENT AND FOLLOW-UP TEAM: Responsible for the confirmatory testing of infants with abnormal results, for the management of confirmed cases and for education of practitioners.

The practitioner’s responsibilities in the program are termed NEWBORN SCREENING PRACTICE (see page 32). A practitioner is defined as the person(s) responsible for supervising the birth and/or the early neonatal care of an infant. Inadequate screening practices can greatly affect the quality of an infant’s screening tests and increase the chances that an affected infant may be missed. At least one-third of cases missed by screening programs in the United States are caused by errors in screening practice.

The central screening laboratory and the follow-up team, together with state health agencies, have developed a quality control program to assist practitioners with their screening practices. Components of this program include ongoing education for practitioners and parents, computerized monitoring of certain screening practices, and an examination of communication channels between practitioners, the laboratory, and the follow-up team.

This manual describes the disorders currently covered by the program, as well as the standards and common problems for certain screening practices, and provides general program information.

DISORDERS COVERED BY THE PROGRAM

In the early 1960s, the most important reason for routine screening in the newborn was to detect and treat phenylketonuria (PKU) in which progressive, profound mental retardation develops in most untreated individuals because the baby cannot metabolize the amino acid phenylalanine. It is now clear that neonatal hypothyroidism is three times as frequent as PKU. While it is possible to test for over 150 different analytes using a few drops of blood applied to a special filter paper, not all are practical. The conditions which are currently tested for in this program are shown in Table 1.

Newborn screening by Tandem Mass Spectrometry (MS/MS) is an effective tool to detect serious and life threatening metabolic disorders in newborns. Using only one to two drops of blood, it is possible to screen for up to 30 separate conditions. For some disorders, like medium chain acyl-CoA dehydrogenase deficiency (MCADD), detection by MS/MS is reliable and early treatment simple and efficacious. Unfortunately, the incidence and efficacy of early diagnosis and treatment for many of the other disorders is unavailable or unproven. As with all conditions, there may be false negative results and practitioners should remain alert for signs of these conditions in infants and children regardless of screening results. Conversely, false positives are possible.

We urge practitioners to use the term “NEWBORN SCREEN,” rather than “PKU test,” since other disorders besides PKU are included in the screening battery. Babies with other disorders have sometimes been mistakenly treated for PKU because any abnormal test result was referred to as a “PKU test.”
<table>
<thead>
<tr>
<th>Condition</th>
<th>Compound Tested for</th>
<th>Incidence</th>
<th>Symptoms if Not Treated</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Endocrine Disorders:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congenital Adrenal Hyperplasia (CAH)</td>
<td>17-OH Progesterone</td>
<td>1:12,000 1:300 in Yupik Eskimos</td>
<td>Addisonian Crisis in all infants; salt wasting in 2/3: dehydration, shock, hyperkalemia; virilization of females</td>
<td>Glucocorticoid and/or mineralocorticoid (Florinef)</td>
</tr>
<tr>
<td>Congenital Hypothyroidism</td>
<td>Thyroid hormones (T₄, with TSH confirmation)</td>
<td>1:3,000</td>
<td>Mental retardation, other brain damage; growth delay</td>
<td>Thyroid hormone (L-Thyroxine)</td>
</tr>
<tr>
<td><strong>Hemoglobin Disorders:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobinopathies including sickle cell anemia</td>
<td>Hemoglobin patterns</td>
<td>1:15,000 1:400 in African Americans</td>
<td>In sickle cell disease: death by sepsis or splenic sequestration anemia, sickling crises</td>
<td>Penicillin &amp; comprehensive care</td>
</tr>
<tr>
<td><strong>Metabolic Disorders:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biotinidase deficiency</td>
<td>Biotinidase</td>
<td>1:60,000</td>
<td>Mental retardation, seizures, skin rash, alopecia, hearing loss, death</td>
<td>Biotin</td>
</tr>
<tr>
<td>Galactosemia</td>
<td>Galactosemia enzyme (GALT)</td>
<td>1:60,000</td>
<td>Severe brain damage; liver disease; cataracts; death</td>
<td>Galactose-restricted diet</td>
</tr>
<tr>
<td><strong>Amino Acids:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arginase Deficiency</td>
<td>Arginine</td>
<td>1:60,000</td>
<td>Irritability; developmental delay; spastic tetraplegia</td>
<td>Low protein diet, medication</td>
</tr>
<tr>
<td>Arginosuccinate Lyase Deficiency (ASA)</td>
<td>Arginine/Citrulline</td>
<td>1:60,000</td>
<td>Hyperammononemia; mental retardation; seizure; death</td>
<td>Low protein diet, medication</td>
</tr>
<tr>
<td>Citrullinemia</td>
<td>Citrulline</td>
<td>1:60,000</td>
<td>Hyperammononemia; mental retardation; seizure; death</td>
<td>Low protein diet, medication</td>
</tr>
</tbody>
</table>
### TABLE I (continued)

**SUMMARY OF DISORDERS SCREENED BY THE PROGRAM**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Compound Tested for</th>
<th>Incidence</th>
<th>Symptoms if Not Treated</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amino Acids (continued):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homocystinuria</td>
<td>Methionine</td>
<td>1:100,000</td>
<td>Mental retardation; dislocation of lenses; marfanoid body habitus</td>
<td>Pyridoxine; methionine restricted, cysteine supplemented diet</td>
</tr>
<tr>
<td>Hyperphenylalaninemia, including phenylketonuria</td>
<td>Phenylalanine</td>
<td>1:10,000</td>
<td>Profound mental retardation; seizures</td>
<td>Low phenylalanine diet</td>
</tr>
<tr>
<td>Tyrosinemia</td>
<td>Tyrosine</td>
<td>1:100,000</td>
<td>Vomiting, lethargy; liver disease; coagulopathy renal tubular acidosis</td>
<td>Medication; low phenylalanine/ low tyrosine diet</td>
</tr>
<tr>
<td>Organic Acidemias:</td>
<td>Acylcarnitines</td>
<td>1:53,000</td>
<td>Neonatal onset: irritability; lethargy; ketoacidosis; coma; death</td>
<td>Dietary therapy/ Medications</td>
</tr>
<tr>
<td>• Beta-ketothiolase deficiency</td>
<td></td>
<td></td>
<td>Late onset; failure to thrive; hypotonia; mental retardation</td>
<td></td>
</tr>
<tr>
<td>• Glutaric acidemia, Type I</td>
<td></td>
<td></td>
<td>Some will be asymptomatic</td>
<td></td>
</tr>
<tr>
<td>• Isobutyryl CoA dehydrogenase deficiency</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Isovaleric acidemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Malonic aciduria</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Maple Syrup Urine Disease (MSUD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Methylmalonic acidemias (8 types)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Propionic acidemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 3-Hydroxy-3-methylglutaryl (HMG) CoA lyase deficiency</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 2-Methyl-3-hydroxybutyryl CoA dehydrogenase deficiency</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 2-Methylbutyryl CoA dehydrogenase deficiency</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 3-Methylcrotonyl CoA carboxylase deficiency</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 3-Methylglutaconyl CoA hydratase deficiency</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Multiple carboxylase deficiency</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### TABLE I (continued)

**SUMMARY OF DISORDERS SCREENED BY THE PROGRAM**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Compound Tested for</th>
<th>Incidence</th>
<th>Symptoms if Not Treated</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fatty Acid Oxidation Defects:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Carnitine uptake/transport defects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Multiple acyl-CoA dehydrogenase deficiency (MADD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Short chain acyl-CoA dehydrogenase deficiency (SCAD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Medium chain acyl-CoA dehydrogenase deficiency (MCAD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Very long chain acyl-CoA dehydrogenase deficiency (VLCAD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acylcarnitines</td>
<td>1:9,300</td>
<td></td>
<td>“Reyes Like” episodes; hypoketotic hypoglycemia; lethargy; cardiomyopathy; hypotonia; mental retardation; coma; death</td>
<td>Dietary therapy/ Medications</td>
</tr>
<tr>
<td>Mother may have had AFLP/HELLP syndrome; acute fatty liver of pregnancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
TABLE II

NORMAL VALUES AND CRITERIA FOR REQUESTING FOLLOW-UP SPECIMENS

<table>
<thead>
<tr>
<th>Analyte</th>
<th>Normal</th>
<th>Phone Follow-up*</th>
<th>Mail Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>17-OH Progesterone</td>
<td>≤ 35 ng/mL ≤ 10 days old, BW &gt; 2500 g</td>
<td>&gt; 70 ng/mL if ≤ 10 days, BW &gt; 2500 g</td>
<td>&gt; 35 to ≤ 70 ng/mL if ≤ 10 days, BW &gt; 2500 g</td>
</tr>
<tr>
<td></td>
<td>≤ 25 ng/mL &gt; 10 days old, BW ≤ 2500 g</td>
<td>&gt; 50 ng/mL if &gt; 10 days, BW &gt; 2500 g</td>
<td>&gt; 25 to ≤ 50 ng/mL if &gt; 10 days, BW &gt; 2500 g</td>
</tr>
<tr>
<td></td>
<td>≤ 60 ng/mL ≤ 10 days old, BW ≤ 2500 g</td>
<td>&gt; 150 ng/mL if ≤ 10 days, BW ≤ 2500 g</td>
<td>&gt; 60 to ≤ 150 ng/mL if ≤ 10 days, BW ≤ 2500 g</td>
</tr>
<tr>
<td></td>
<td>≤ 40 ng/mL &gt; 10 days old, BW ≤ 2500 g</td>
<td>&gt; 100 ng/mL if &gt; 10 days, BW ≤ 2500 g</td>
<td>&gt; 40 to ≤ 100 ng/mL if &gt; 10 days, BW ≤ 2500 g</td>
</tr>
<tr>
<td>Thyroxine (T₄)</td>
<td>Upper 90% of T₄ determinations</td>
<td>T₄ in lower 10% and TSH &gt; 100 µIU/mL</td>
<td>T₄ in lower 3% on 2 specimens and TSH normal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T₄ in lower 10% and TSH &gt; 50 in &gt; 72 hours old</td>
<td>T₄ &lt; 5.0 µmg/dL, TSH normal (premature baby)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>T₄ in lower 10% and TSH 25 to 50 µIU/mL if &gt; 72 hours old and TSH 35 to 100 µIU/mL if &lt; 72 hours old</td>
</tr>
<tr>
<td>TSH</td>
<td>&lt; 35 µIU/mL if ≤ 72 hours old</td>
<td>&gt; 100 µIU/mL if ≤ 72 hours old</td>
<td>35.1–100 µIU/mL if ≤ 72 hours old</td>
</tr>
<tr>
<td></td>
<td>&lt; 25 µIU/mL if &gt; 72 hours old or older</td>
<td>&gt; 50 µIU/mL if &gt; 72 hours old</td>
<td>25.1–50.0 µIU/mL</td>
</tr>
<tr>
<td>Hemoglobin IEF</td>
<td>Hgb F and A</td>
<td>Probable homozygote</td>
<td>Probable homozygote</td>
</tr>
<tr>
<td>Biotinidase</td>
<td>Activity present</td>
<td>Partial Activity</td>
<td></td>
</tr>
<tr>
<td>Galactosemia Enzymes (Gal-1-PO₄ uridyl transferase, GALT)</td>
<td>Fluorescence present</td>
<td>No fluorescence and galactose ≥ 20 mg/dL or galactose &lt; 20 mg/dL if &lt; 48 hours old</td>
<td>No fluorescence and galactose, &lt; 20 mg/dL, age ≥ 48 hours</td>
</tr>
<tr>
<td>Arginine</td>
<td>&lt; 140 µM</td>
<td>≥ 210 µM</td>
<td>≥ 140 µM but &lt; 210 µM</td>
</tr>
<tr>
<td>Citrulline</td>
<td>&lt; 90 µM</td>
<td>≥ 90 µM with a normal 1st specimen</td>
<td>≥ 90 µM - &lt; 200 µM with a normal 1st specimen</td>
</tr>
<tr>
<td>Leucine</td>
<td>&lt; 300 µM</td>
<td>≥ 300 µM, Leu/Ala ≥ 1.75 µM</td>
<td>≥ 300 µM, Leu/Ala &lt; 1.75 µM and elevation of other amino acids and on hyperalimentation (TPN)</td>
</tr>
<tr>
<td>Leucine/Alanine Ratio</td>
<td>&lt; 1.75 µM</td>
<td>≥ 300 µM, Leu/Ala ≥ 1.75 µM</td>
<td>≥ 80 µM but &lt; 120 µM</td>
</tr>
<tr>
<td>Methionine</td>
<td>&lt; 80 µM</td>
<td>≥ 120 µM</td>
<td>≥ 80 µM but &lt; 120 µM</td>
</tr>
<tr>
<td>Phenylalanine</td>
<td>&lt; 200 µM</td>
<td>≥ 200 µM, Phe/Tyr ≥ 3.0 µM</td>
<td>≥ 200 µM, Phe/Tyr &lt; 3.0 µM</td>
</tr>
<tr>
<td>Phenylalanine/Tyrosine Ratio</td>
<td>&lt; 3.0 µM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tyrosine</td>
<td>&lt; 475 µM</td>
<td>≥ 713 µM</td>
<td>≥ 475 µM but &lt; 713 µM</td>
</tr>
</tbody>
</table>

*All phoned results are followed by mailed confirmation. All of these tests are screening tests. Abnormal results need full evaluation/discussion with a consultant before a diagnosis is confirmed or treatment is started. Normal and abnormal values are subject to change based on continuing statistical evaluation.
### TABLE II (continued)

**NORMAL VALUES AND CRITERIA FOR REQUESTING FOLLOW-UP SPECIMENS**

<table>
<thead>
<tr>
<th>Analyte</th>
<th>Normal</th>
<th>Phone Follow-up*</th>
<th>Mail Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Organic Acidemias:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C3 (Propionyl) Propionic acidemia,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylmalonic acidemias (8 types), Multiple</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>carboxylase deficiency</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C3-DC (Dicarboxyl Propionyl) Malonic Aciduria</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C4 (Butyryl/Isobutyryl) Isobutyryl CoA dehydrogenase deficiency, MADD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C4-DC (Methylmalonyl) Methylmalonic acidemias (8 types)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C5 (Isovaleryl/2-Methyl-butyryl) Isovaleric acidemia, 2-Methyl-3-hydroxybutyryl CoA dehydrogenase deficiency</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C5:1 (Tiglyl/3-Methylcrotonyl) 3-Methylcrotonyl CoA carboxylase deficiency (3-MCC), Beta-ketothiolase deficiency</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C5-DC (Glutaryl) Glutaric acidemia, Type I,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C6-DC (Methylglutaryl) HMG-CoA lyase deficiency, Malonic aciduria, Multiple carboxylase deficiency</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fatty Acid Oxidation Defects:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C0 (free carnitine) Carnitine uptake/transport defects</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C4 (Butyryl/Isobutyryl) SCAD Deficiency, Multiple acyl-CoA dehydrogenase deficiency (MADD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C5 (Isovaleryl/2-Methyl-butyryl) MADD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C5-DC (Glutaryl) MADD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C6 (Hexanoyl) MCAD Deficiency, MADD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C8 (Octanoyl) MCAD Deficiency, MADD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C10 (Decanoyl) MCAD Deficiency, MADD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C10:h1 (Decenoyl) MCAD Deficiency</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C14 (Tetradecanoyl) VLCAD Deficiency, MADD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C14:h1 (Tetradecanoyl) VLCAD Deficiency</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C16 (Palmitoyl) VLCAD Deficiency, LCHAD Deficiency, MADD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C16-OH (Hydroxy Palmitoyl) LCHAD Deficiency</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C18 (Octadecanoyl) VLCAD Deficiency</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C18:h1 (Oleoyl) MADD</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

All abnormal results will be phoned until the significance of minor abnormalities is determined.
CONGENITAL ADRENAL HYPERPLASIA (CAH)

Congenital adrenal hyperplasia is an inherited defect of cortisol synthesis. The adrenal gland cannot make cortisol and overproduces male hormones. Without cortisol, infants are at risk for adrenal crisis and may be unable to regulate salt and fluids, and can die. The incidence of 21-hydroxylase deficiency is 1:12,000 live births. The incidence is 1:300 in certain Yupik Eskimo populations.

Clinical Features

Unlike some other disorders in newborn screening, infants may be symptomatic at birth. By four to five months gestation, diminished cortisol production stimulates the fetal pituitary gland to produce ACTH and excessive adrenal androgens. The androgens virilize female external genitalia, but ovaries and uterus are unaffected. Male infants may have increased scrotal pigmentation or may be asymptomatic.

In two-thirds of cases, the 21-hydroxylase deficiency causes reduced production of mineralocorticoids. This leads to a hypotensive, hyperkalemic, salt-losing crisis with rapid onset of adrenocortical failure within 7–28 days of birth. This can be fatal. In one-third of cases, the infant has a “non-salt losing” or “simple virilizing form.” If untreated, children have mild postnatal virilization, rapid growth with advanced skeletal age, early puberty, and short stature as adults. In adulthood, there is hirsutism and acne. Women have irregular menses and infertility.

Causes of CAH

The term “congenital adrenal hyperplasia” or “adrenogenital syndrome” covers a group of disorders. All are due to an inborn error of steroid hormone synthesis, which blocks the production of cortisol. The low level of cortisol stimulates ACTH, causing adrenal hyperplasia and increased secretion of steroid precursors. Different enzyme defects block the metabolic pathway at different sites and result in different clinical features. The most common disorder is 21-hydroxylase deficiency, which is the disorder tested for on newborn screening. There are variants to this disorder, which have later onset. All forms of CAH are inherited as autosomal recessive disorders.

Laboratory Tests

Screening is based on an immunoassay for a precursor steroid, 17-hydroxyprogesterone (17-OHP). Affected infants have high levels of 17-OHP. Infants with milder disorders have intermediate levels. False positives may occur in preterm, low birthweight and sick infants.

Confirmation

Confirmation is by measurement of serum 17-OHP and if salt wasting is suspected, sodium, potassium and plasma renin.

Treatment

Infants should be treated with hydrocortisone and mineralocorticoids in consultation with a pediatric endocrinologist. Infants with ambiguous genitalia need chromosome analysis to confirm gender.

Screening Practice Considerations

Female infants who are virilized or infants with ambiguous genitalia should be considered at risk for this condition, tested at birth, and monitored for electrolyte abnormalities until the diagnosis is excluded. Male infants are not usually recognized at birth. In both sexes, salt wasting and shock may develop rapidly within 7–28 days of birth. Approximately five to ten percent of infants will be detected only on a second screen. This disease kills quickly. Transport all specimens four to six hours after collection and no later than 24 hours.

<table>
<thead>
<tr>
<th>RESULT</th>
<th>LIKELY CAUSES</th>
<th>ACTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>17-OHP &gt;70 ng/mL, &lt;10 days old, BW &gt;2500 g</td>
<td>* CAH probable</td>
<td>Neonatal emergency; Oregon medical consultant contacts infant’s physician by telephone and facsimile.</td>
</tr>
<tr>
<td>17-OHP &gt;150 ng/mL, &lt;10 days old, BW &lt;2500 g</td>
<td>* False positive</td>
<td></td>
</tr>
<tr>
<td>17-OHP&gt;50 ng/mL, &gt;10 days old, (any birth weight)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17-OHP&gt;35–&lt;70 ng/mL, &lt;10 days old, BW &gt;2500 g</td>
<td>* Mild CAH</td>
<td>Oregon laboratory notifies practitioner by letter with request to repeat filter paper sample.</td>
</tr>
<tr>
<td>17-OHP&gt;25–&lt;50 ng/mL, &gt;10 days old, BW &gt;2500 g</td>
<td>* False positive</td>
<td></td>
</tr>
<tr>
<td>17-OHP&gt;50–&lt;150 ng/mL, &lt;10 days old, BW &lt;2500 g</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17-OHP&gt;40–&lt;100 ng/mL, &gt;10 days old, BW ≤2500 g</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**CONGENITAL HYPOTHYROIDISM**

Congenital hypothyroidism occurs in babies who are born without the ability to produce adequate amounts of thyroid hormone. Thyroid hormone is important for normal function of all of the body’s organs and is essential for normal brain development. The incidence of congenital hypothyroidism is 1:3,000. Newborn screening for congenital hypothyroidism is done in all states in our regional program.

**Clinical Features**

Deficiency of thyroid hormone in an infant may result in mental retardation and other signs of brain damage if it is not diagnosed and treated early in life. Many infants with congenital hypothyroidism may appear clinically normal before three months of age, by which time some brain damage has usually occurred. Only five percent of our cases were suspected by their doctor before the results of the screening were known. Laboratory test results are the only reliable means of diagnosing congenital hypothyroidism in the newborn.

When symptoms or signs are present, they may include prolonged neonatal jaundice, constipation, lethargy and poor muscle tone, feeding problems, a large tongue, puffy face, large fontanelle, distended abdomen and umbilical hernia. Since thyroid deficiency can occur at any age, normal tests in the newborn period do not exclude deficiency in an older infant or child.

**Causes of Congenital Hypothyroidism**

The most common causes are total or partial failure of the thyroid gland to develop (aplasia or hypoplasia), or its development in an abnormal location (an ectopic gland). Less commonly, hypothyroidism is induced by medications (antithyroid drugs or excess iodine) in the mother, or maternal autoimmune thyroid disease with transfer of a maternal antibody which blocks the fetal thyroid development.

**Laboratory Tests**

The initial screening test is the T4 (thyroxine) assay. The 10 percent of samples with the lowest T4 results are further tested by a screening TSH assay. Different combinations of results are possible; see table below. When the infant’s physician is notified that screening results are abnormal, blood should be collected by venipuncture as soon as possible to confirm the

<table>
<thead>
<tr>
<th>RESULT</th>
<th>LIKELY CAUSES</th>
<th>ACTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>T4 low/TSH elevated</td>
<td>* Hypothyroidism probable</td>
<td>Lab will contact practitioner by phone and send letter requesting serum testing</td>
</tr>
<tr>
<td></td>
<td>* False positive</td>
<td></td>
</tr>
<tr>
<td>T4 &lt; 3.0 µg/dL, TSH pending</td>
<td>* Prematurity</td>
<td>Lab will contact practitioner by phone and send letter requesting further tests</td>
</tr>
<tr>
<td></td>
<td>* Hypothyroidism possible</td>
<td></td>
</tr>
<tr>
<td></td>
<td>* False positive</td>
<td></td>
</tr>
<tr>
<td>T4 low/TSH normal (on one or two specimens unless premature)</td>
<td>* Thyroid binding globulin (TBG) deficiency</td>
<td>Lab will contact practitioner by letter for further tests</td>
</tr>
<tr>
<td></td>
<td>* False positive</td>
<td></td>
</tr>
<tr>
<td></td>
<td>* Pituitary gland problem with secondary hypothyroidism</td>
<td></td>
</tr>
<tr>
<td></td>
<td>* Prematurity - see below</td>
<td></td>
</tr>
</tbody>
</table>
abnormal screening results. In the case where the T4 is low and TSH is elevated, treatment can be started as soon as the serum is obtained, pending final confirmation. If the serum thyroid function tests confirm hypothyroidism, further diagnostic studies, such as a thyroid scan and bone age X-ray, may be desirable to determine the type, age of onset and severity of hypothyroidism. Generally, these studies do not change management and so are optional.

**Thyroid Function in Premature Infants**

In premature infants, there is a physiological reduction in blood T4 levels, TSH levels are not elevated in this situation. These cases need special observation to ensure that the low T4 levels rise into the normal range as the infant matures, but this may take several weeks.

**Treatment**

Treatment of congenital hypothyroidism is simple and effective. Thyroxine (e.g. Synthyroid, levoxyl or levothyroid), in pill form, is crushed, mixed with milk and administered once daily. The usual starting dose is 10-15 microgram/kg of body weight daily, usually 37.5 mcg/kg to 50 mcg/kg (1 1/2-2 of 25 mcg tablets). The American Academy of Pediatrics (AAP), recommends follow-up serum T4 (or free T4) and TSH as follows:

- Initiation of treatment: two and four weeks later
- First year: every one to two months
- Second and third year: every two to three months
- Thereafter: every 3-12 months

Treatment goals: serum T4 in the upper 1/2 of the normal range (10-16µg/dL) and TSH normalized (<10 µIU/mL). Clinical evaluations can occur less frequently. As infants grow, the dose of thyroxine is increased. Infants should also undergo periodic developmental testing. If treatment is started early and thyroid levels are monitored closely, the development remains normal.

**Screening Practice Considerations**

Hypothyroidism is the most common disorder covered by the program. Ninety percent of hypothyroid infants are detected on the first specimen even if it is collected a few hours after birth. In 10 percent of cases, hypothyroidism only develops in the weeks after birth and is detected on a second screening test as production of thyroid hormone dwindles after birth. Practitioners therefore must remain alert to clinical symptoms in older infants despite normal initial screening.

False positive results may occur if the specimen is collected with the first few hours after birth, as the TSH rises in response to the extrauterine environment. Topical iodine may cause transient hypothyroidism in prematures.

---

The purpose of newborn screening is to identify infants at risk and in need of more definitive testing. As with any laboratory test, both false negative and false positive results are possible. Screening test results are insufficient information on which to base diagnosis or treatment.
SICKLE CELL DISEASE AND OTHER HEMOGLOBINOPATHIES

The primary goal of hemoglobinopathy screening is diagnosis of significant sickling hemoglobinopathies in the neonatal period, before symptoms occur. Newborn diagnosis of sickle cell disease, if coupled with family education and centralized comprehensive care, can markedly lower morbidity and mortality.

Homozygous sickle cell disease (SCD) occurs when the recessive gene for hemoglobin S, sickle hemoglobin, is inherited from both parents. The term “clinically significant sickling syndrome” also includes conditions resulting from inheritance of one gene for hemoglobin S and certain other unusual hemoglobins, such as beta thalassemia or hemoglobin C. These doubly heterozygous conditions tend to be less severe than SCD, though all are capable of producing severe complications. The incidence of SCD in the African American population is 1:400, but also occurs at a lower frequency among all other ethnic groups. The disease incidence in a population depends on the population’s ethnic composition.

Clinical Features

Sickle syndromes are systemic diseases and may involve any organ. They are characterized clinically by chronic hemolysis, intermittent vaso-occlusion and marked variability. Some patients experience unremitting complications, others lead a full and productive life. Early manifestations are often life-threatening and include overwhelming infection due to splenic dysfunction, splenic sequestration crisis, and aplastic crisis with profound anemia. Prior to newborn diagnosis and preventive care, mortality in the United States was 8-30 percent in the first three years of life. Some important complications include vaso-occlusive pain syndromes, osteomyelitis, acute chest syndrome, stroke, priapism, pyelonephritis, gallstones, skin ulcers, retinopathy, and decreased life expectancy.

Other significant hemoglobinopathies are less common and even more variable. Their manifestations range from very mild chronic hemolysis to severe dyserythropoiesis requiring a lifetime of transfusion support. Early detection of these, however, may prevent unnecessary diagnostic and therapeutic intervention.

Laboratory Tests

Screening for sickle cell disease is done using dried blood spots submitted for newborn screening tests. All first filter paper samples are screened for hemoglobinopathies using isoelectric focusing (IEF). Various hemoglobin patterns occur. If an abnormality is detected, the sample is reanalyzed using high performance liquid chromatography (HPLC). If a hemoglobin abnormality is detected on the first filter paper sample, the second filter paper sample is also analyzed by IEF and HPLC. Thus, each hemoglobin abnormality is verified four times, using two different techniques on two different samples. Solubility tests (Sickle-dex, Sickle-prep, etc.) are never appropriate in infancy and should not be used to confirm screening results.
<table>
<thead>
<tr>
<th>RESULTS</th>
<th>LIKELY CAUSE</th>
<th>ACTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>FS (absence of A)</td>
<td>* Sickle cell disease or Sickle beta thalasemia</td>
<td>Lab will report to follow-up team who contacts practitioner by phone with instructions for diagnosis and treatment</td>
</tr>
<tr>
<td>FSC (absence of A)</td>
<td>* Sickle hemoglobin SC disease</td>
<td>Lab will report to follow-up team who contacts practitioner by phone with instructions for diagnosis and treatment</td>
</tr>
<tr>
<td>FC (absence of A)</td>
<td>* Homozygous C disease</td>
<td>Lab will report to follow-up team who contacts practitioner by phone with instructions for diagnosis and treatment</td>
</tr>
<tr>
<td>FE (absence of A)</td>
<td>* Homozygous hemoglobin E or hemoglobin E-beta thalasemia</td>
<td>Lab will report to follow-up team who contacts practitioner by phone with instructions for diagnosis and treatment</td>
</tr>
<tr>
<td>FAS</td>
<td>* Sickle cell carrier &lt;br&gt; * Sickle beta thalasemia &lt;br&gt; * Sickle cell disease in transfused infant</td>
<td>Lab will report by letter regarding test results and any other recommendations</td>
</tr>
<tr>
<td>FAC</td>
<td>* Hemoglobin C carrier &lt;br&gt; * Homozygous C disease in a transfused infant</td>
<td>Lab will report by letter regarding test results and any other recommendations</td>
</tr>
<tr>
<td>FA+slow band</td>
<td>* Possible carrier for hemoglobin E, O, D, or G</td>
<td>Lab will report by letter regarding test results and any other recommendations</td>
</tr>
<tr>
<td>FA+fast band</td>
<td>* Possible alpha thalasemia &lt;br&gt; * Bart’s hemoglobin is a marker for alpha thalasemia</td>
<td>Lab will report by letter regarding test results and any other recommendations</td>
</tr>
<tr>
<td>F only</td>
<td>* Premature infant &lt;br&gt; * Beta thalasemia major</td>
<td>Lab will report by letter regarding test results and any other recommendations</td>
</tr>
<tr>
<td>Predominance of A</td>
<td>* Transfused infant &lt;br&gt; * Patient outside of neonatal age range</td>
<td>Lab will report by letter regarding test results and any other recommendations</td>
</tr>
</tbody>
</table>

**Treatment**

Infants with significant hemoglobinopathies should have a primary care provider and receive periodic evaluation in a comprehensive care setting. Therapy begins with education of care-givers and includes prophylactic penicillin, prompt evaluation and empirical treatment of any febrile illness, and immunizations including those for encapsulated bacteria. Close attention is necessary for the common problems of poor growth, recurrent pain and febrile illnesses. Organ-specific complications, sedation and general anesthesia require special attention. Other treatments, including the use of blood products and investigational therapies depend on clinical course.
Carrier Detection Makes Hemoglobin Screening Different

This is the only newborn screening test which regularly identifies carriers (heterozygotes) as well as those affected by a given disease. In fact, many more carriers than disease states are identified for all hemoglobinopathies. If both parents are carriers of an autosomal recessive genetic trait, the risk of any infant of that couple being homozygous is 1/4. While the best way to handle this genetic information has yet to be agreed upon, several principles are currently operative: 1) The family is entitled to the information and it is private. 2) If both parents of a SCD carrier infant are African American, they have at least a 1/50 risk of having a subsequent child with SCD, because at least one of them is now known to be a carrier. The family should be offered testing and genetic counseling. If the family declines participation, this should be documented. 3) The abnormal screening results may need to be confirmed, using a liquid blood specimen. The Medical Consultant for hemoglobinopathy screening is available for assistance.

Screening Practice Considerations

Newborn screening for hemoglobinopathies is not done on the second specimen unless an abnormality has been identified on the first specimen. It is crucial to use the first kit for the first test; the cards are not interchangeable. Transfusion of red blood cells prior to drawing the newborn screening specimen will invalidate the hemoglobinopathy test. **Obtain a specimen before any transfusion.** Some hemoglobinopathies, particularly the thalassemias, are not reliably detected through newborn screening and a normal screening result does not eliminate the possibility that a patient has a hemoglobinopathy. Further testing or consultation should be sought if indicated by clinical suspicion.

The purpose of newborn screening is to identify infants at risk and in need of more definitive testing. As with any laboratory test, both false negative and false positive results are possible. Screening test results are insufficient information on which to base diagnosis or treatment.
**BIOTINIDASE DEFICIENCY**

Detection of biotinidase deficiency requires urgent follow-up. This recessively inherited disorder affects the regeneration of the vitamin-cofactor biotin and impairs the metabolism of mitochondrial carboxylases. The incidence is estimated at 1:60,000 births. Screening for biotinidase deficiency is performed in all the states in our regional program.

**Clinical Features**

Infants with biotinidase deficiency are normal at birth, but develop one or more of the following symptoms after the first weeks or months of life: hypotonia, ataxia, seizures, developmental delay, alopecia, seborrheic dermatitis, hearing loss and optic nerve atrophy. Metabolic acidosis can result in coma and death.

**Laboratory Tests**

Detection of enzyme activity is by a qualitative colorimetric assay. In the presence of the enzyme a color change occurs.

<table>
<thead>
<tr>
<th>RESULTS</th>
<th>LIKELY CAUSES</th>
<th>ACTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Color change does not occur</td>
<td>* Biotinidase deficiency possible * False positive</td>
<td>Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail.</td>
</tr>
</tbody>
</table>

**Treatment**

Daily biotin supplements clear the skin rash and alopecia and improve the neurological status in patients not diagnosed by screening. With early diagnosis and treatment made possible by screening, all symptoms can be prevented.

**Screening Practice Considerations**

The enzyme is prone to damage if the sample is delayed in the mail or exposed to high temperatures. Transfusion of red cells prior to drawing the newborn screening specimen will invalidate the biotinidase assay. **Obtain a specimen before transfusion.**

The purpose of newborn screening is to identify infants at risk and in need of more definitive testing. As with any laboratory test, both false negative and false positive results are possible. Screening test results are insufficient information on which to base diagnosis or treatment.
GALACTOSEMIA

Detection of galactosemia requires urgent follow-up and should be considered a potential medical emergency. Dietary galactose is most commonly ingested as lactose, the principle carbohydrate of human milk and most non-soy commercial infant formulas; it is hydrolyzed to glucose and galactose in the intestine. After absorption it is metabolized by several enzymes including galactokinase and galactose-1-phosphate uridyl transferase (GALT). When deficient, the latter causes galactosemia (1:60,000 births). Galactosemia is a recessively inherited condition and screening is performed in all the states in our regional program.

Clinical Features
The early clinical features of severe untreated galactosemia include neonatal hypoglycemia, liver damage, jaundice, failure to thrive, lethargy and sepsis. Vitreous hemorrhage has been reported in some infants. Death may result from gram-negative sepsis within one to two weeks of birth. If the infant is untreated and survives the neonatal period, cataracts, cirrhosis, renal Fanconi syndrome and mental retardation are usual.

There are several genetic variants with less severe reduction in the enzyme activity (e.g., the Duarte variant). Most of these cases are asymptomatic and are detected on newborn screening because of abnormalities. Recommendations for confirmatory testing are made by the medical consultants. The need for treatment of Duarte variant galactosomia is controversial and the consultants are available for consultation. The screening test is not designed to detect Duarte variant galactosemia and is not completely sensitive for this purpose.

Laboratory Tests
Two screening tests are used to detect galactosemia in a two tiered sequence (see diagram):

1. GALT activity (Beutler Test):
   The enzyme test depends upon fluorescence produced by the normal galactose enzyme cascade in red blood cells. A temporarily abnormal result (diminished or absent fluorescence) is found in 1:2,000 infants. The test

<table>
<thead>
<tr>
<th>RESULTS</th>
<th>LIKELY CAUSES</th>
<th>ACTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>GALT Test</td>
<td>Galactose Metabolites</td>
<td></td>
</tr>
</tbody>
</table>
| Abnormal | ≥20 mg/dL | * Severe galactosemia  
* Variant galactosemia  
* False positive | Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail. |
| Abnormal | <20 mg/dL | * Severe galactosemic with little lactose intake  
* Variant galactosemia  
* Other enzyme defects in red blood cells  
* Improperly handled sample (heat damage or transit delay) | Contact by letter if >48 hrs old; contact by phone if < 48 hrs old or if not on lactose |
may be persistently abnormal if the enzyme activity is <50% of normal. It does not differentiate milder variants from severe defects. All infants are screened with the Beutler test.

(2) Galactose (Hill Test):
Slight elevations (up to 20 mg/dL) can occur in normal neonates, but galactose metabolites are greatly elevated in infants with galactosemia if they are receiving a lactose-containing formula or breast milk. The Hill test is a fluorometric chemical spot test which measures galactose and galactose-1-phosphate. Liver disease may also cause an elevation of galactose metabolites. Only infants with an abnormal Beutler or who have been transfused will be screened with the Hill Test.

**Galactosemia**

Galactosemia is treated by dietary galactose restriction. This diet must be followed for life and requires close supervision. Even with early diagnosis and strict dietary restrictions children with galactosemia are at risk for speech disorders, growth and developmental delays and in females, ovarian failure.

**Screening Practice Considerations**

The GALT test should be abnormal in virtually all severe classic galactosemic infants even if the specimen is obtained before lactose is ingested, unless the infant has been transfused. **Obtain a specimen before any transfusion.** The GALT test is prone to inaccuracy if the sample is delayed in the mail or exposed to high temperature or humidity.

Galactose accumulation depends on **lactose** ingestion so that blood galactose metabolites may be normal in infants receiving soy based formula. This disease kills quickly. Transport all specimens four to six hours after collection and no later than 24 hours after collection.
AMINO ACID DISORDERS

UREA CYCLE DISORDERS *

The urea cycle is the metabolic pathway responsible for the detoxification of ammonia and for the synthesis of arginine and urea. There are six enzymes in the urea cycle, each of which if missing, will result in hyperammonemia. Six disorders, each with genetic and clinical variability have been reported, each representing one of the enzymes of the urea cycle. Three of these disorders can be detected in newborn screening tests*:

1. Arginase deficiency
2. Argininosuccinic aciduria
3. Citrullinemia

Estimated incidence of these conditions is 1:60,000. They are inherited as autosomal recessive traits.

Arginase Deficiency

Clinical Features

Arginase deficiency is associated with irritability, unconsolable crying, anorexia, vomiting and developmental delay in infancy. This progresses to spastic tetraplegia with lower limbs more severely affected than the upper, psychomotor retardation, hyperactivity and growth failure. Hyperammonemia may result in encephalopathy, but is often milder than that seen in other urea cycle defects.

Citrullinemia & Argininosuccinic Aciduria

Clinical Features-Neonatal Onset

Infants with severe citrullinemia and argininosuccinic aciduria appear normal at birth and for the first 24 hours. Usually between 24-72 hours symptoms of hyperammonemia will appear as lethargy, vomiting, hypothermia, hyperventilation progressing to coma, cerebral edema and death without intervention. Unfortunately, a misdiagnosis of sepsis is made in 50% of the cases, wasting precious time. In addition to ammonia, glutamate/glutamine are usually elevated. Specific elevations in citrulline, argininosuccinic acid, arginine, and orotic acid are helpful in determining the type of urea cycle defect.

Clinical Features-Late Onset

Late onset forms of urea cycle defects most often present as non-specific developmental delay, seizures or other neurological symptoms which are associated with a history of repeated bouts of lethargy, vomiting, irritability or headaches. Food refusal and failure to thrive are not uncommon.

Laboratory Tests

Elevations of citrulline and arginine are detected by MS/MS. The laboratory cutoff for citrulline is <90 µM; for arginine <140 µM. Argininosuccinic acid cannot be distinguished from citrulline using tandem mass spectrometry. Transient elevations of plasma arginine and citrulline in the newborn are unusual unless the infant is premature and/or receiving hyperalimentation.

* Screening will NOT identify all urea cycle disorders and sensitivity and specificity for Arginase deficiency is unknown. Practitioners should remain alert to the possibility of hyperammonemia in any infant with lethargy and coma in the first few days of life.
## Treatment

All patients with a neonatal presentation represent medical emergencies and outcomes may be variable. Patients with neonatal onset disease will typically require aggressive treatment with hemodialysis. All patients, both late onset and those rescued from neonatal hyperammonemia, will require treatment with low protein diets and medications to prevent hyperammonemia and remove toxic compounds. The outcome for patients rescued from prolonged neonatal hyperammonemia is dismal. Brain damage is likely. Even patients treated prospectively from birth may not be normal. Those with late onset disease fare better, and presymptomatic diagnosis and treatment may allow normal development.

### Screening Practice Considerations

Infants with neonatal onset disease may be sick or die before screening results are known. Collect specimens before discharge and transport within four to six hours of collection and no longer than 24 hours after collection. Practitioners must remain alert to the possibility of these disorders in any newborn with lethargy or coma.

---

<table>
<thead>
<tr>
<th>RESULTS</th>
<th>LIKELY CAUSES</th>
<th>ACTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arginine &gt; 210 µM</td>
<td>* Arginase deficiency possible * Transient argininemia * Liver disease * False positive</td>
<td>Lab phones results to consultants, who phone practitioner with recommenda-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>tion. Notification is followed up by mail.</td>
</tr>
<tr>
<td>Citrulline ≥ 90 µM</td>
<td>* Citrullinemia, argininosuccinic aciduria possible * Transient citrullinemia</td>
<td>Lab phones results to consultants, who phone practitioner with recommenda-</td>
</tr>
<tr>
<td>Citrulline ≥ 200 µM on second specimen</td>
<td>* Liver disease * False positive</td>
<td>tion. Notification is followed up by mail.</td>
</tr>
<tr>
<td>Citrulline ≥ 90 µM - &lt; 200 µM with a normal 1st specimen</td>
<td>* Mild citrullinemia, argininosuccinic aciduria possible * Transient citrullinemia</td>
<td>Lab requests repeat filter paper specimen</td>
</tr>
<tr>
<td></td>
<td>* Liver disease * False positive</td>
<td></td>
</tr>
</tbody>
</table>

---

The purpose of newborn screening is to identify infants at risk and in need of more definitive testing. As with any laboratory test, both false negative and false positive results are possible. Screening test results are insufficient information on which to base diagnosis or treatment.
HYPERMETHIONINEMIA

Homocystinuria (cystathionine beta-synthase deficiency) *

The most common form of genetic homocystinuria is cystathionine beta-synthase deficiency (CBS). CBS is required for conversion of methionine to cysteine and deficiency results in the accumulation of homocystine, methionine and cysteine-homocystine disulfides in the blood and urine. Unfortunately, methionine rises slowly in affected infants and may not be detectable on specimens obtained in the first few days after birth. Homocystinuria is inherited as an autosomal recessive trait. Occurs in approximately 1:100,000 births.

Clinical Features

Untreated patients appear normal at birth, but by the first or second year mental retardation may be apparent, most will develop dislocation of the lenses and a marfanoid body habitus, osteoporosis, and ultimately thromboembolism may develop which can result in serious and permanent disabilities or death.

Methionine Adenosyltransferase (MAT) Deficiency

Approximately 20 infants in the U.S., identified through newborn screening with persistently elevated methionine have been shown to have MAT deficiency. All but two patients have been asymptomatic, with normal growth and development. Two patients have had demyelination of the brain, but it is not clear that this is a result of MAT deficiency or other causes.

Laboratory Test

Elevation of methionine is detected by MS/MS; normal methionine levels are <80 µM. Transient elevations of plasma methionine in the newborn is unusual unless the infant is premature and/or receiving IV amino acid preparations. (i.e., TPN, hyperalimentation).

* Not all forms of homocystinuria or even all cases of CBS deficiency will be detected by MS/MS.

<table>
<thead>
<tr>
<th>RESULTS</th>
<th>LIKELY CAUSES</th>
<th>ACTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methionine ≥ 80 –120 µM</td>
<td>* Homocystinuria/MAT deficiency possible</td>
<td>Lab requests repeat filter paper specimen by mail</td>
</tr>
<tr>
<td></td>
<td>* Tyrosinemia, Type 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>* Liver disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>* Hyperalimentation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>* High protein diet</td>
<td></td>
</tr>
<tr>
<td></td>
<td>* False positive</td>
<td></td>
</tr>
<tr>
<td>Methionine ≥ 120 µM</td>
<td>* Homocystinuria/MAT deficiency probable</td>
<td>Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail</td>
</tr>
<tr>
<td></td>
<td>* Tyrosinemia, Type 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>* Liver disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>* Hyperalimentation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>* High protein diet</td>
<td></td>
</tr>
<tr>
<td></td>
<td>* False positive</td>
<td></td>
</tr>
</tbody>
</table>
The purpose of newborn screening is to identify infants at risk and in need of more definitive testing. As with any laboratory test, both false negative and false positive results are possible. Screening test results are insufficient information on which to base diagnosis or treatment.

Treatment

Some patients will respond to pyridoxine in large doses (250-1200 mg/day). For patients unresponsive or partially responsive to pyridoxine, a methionine restricted, cysteine supplemented diet is usually effective. Betaine is usually effective. The outcome for treated patients is dependent on the age at diagnosis, adherence with therapy and severity of defect.

Screening Practice Considerations

Methionine rises slowly in affected infants, so that the first screening specimen may be normal; 80% of the homocystinuria patients detected in the NWRNBSI have been found on routine second tests.
PHENYLKETONURIA (PKU) & HYPERPHENYLALANINEMIA

Detection of elevated phenylalanine levels requires urgent follow-up. This disorder is due to a recessively inherited enzyme defect in which the body cannot use the amino acid phenylalanine properly. All other metabolic processes are intact, but phenylalanine, which comes from all dietary protein, accumulates in the blood to toxic levels. Screening for PKU is performed in all states in our regional program.

Clinical Features

Infants with PKU seem to be normal for many months, however, without treatment, severe mental retardation, eczema and other problems usually develop. In older untreated patients the skin and hair may be fair, the eyes may be blue and a mousey odor of the skin or urine is common. Untreated blood phenylalanine level is often over 1200 µM.

Overall, PKU occurs in about 1 in 10,000-15,000 Caucasian and Hispanic births. It is less common in other races, but the racial frequency distribution is not well known. Although severe mental deficiency is the rule in untreated cases, occasional asymptomatic adults are found with normal or near normal intelligence, despite high phenylalanine levels.

Plasma phenylalanine is not detectably elevated in cord blood. It starts rising within 24 hours after birth and often reaches 1200 µM or more within a few days. The screening test is often abnormal within 24 hours and almost uniformly abnormal within 48 hours of birth.

Variant Forms of PKU (Hyperphenylalaninemia)

There are several intermediate forms of hyperphenylalaninemia in which the plasma phenylalanine levels are lower than in classic PKU (180-1200 µM). In these cases, mental retardation is variable and, in the milder variants, is completely absent. In infancy, these patients can mimic severe PKU, and for adult women the risk of the maternal PKU syndrome increases in proportion to the plasma phenylalanine.

Some forms of hyperphenylalaninemia are caused by defects of biopterin metabolism and blood phenylalanine levels are variable. These patients have progressive neurological damage with seizures and steady deterioration which becomes noticeable sometime between 6 and 20 months of age despite early treatment with a low phenylalanine diet. Definitive tests can differentiate these variant forms of PKU.

In view of the severity of this group of diseases, all infants with persistently abnormal levels of phenylalanine will be recommended to have testing by special blood and urine tests for biopterin abnormalities. Information regarding this testing is provided through the metabolic consultants.

Maternal PKU and Hyperphenylalaninemia

Women with significant hyperphenylalaninemia have an increased risk of miscarriage and their offspring (who usually do not have PKU) may have intra-uterine growth retardation which persists postnatally. More than 90 percent of infants of untreated mothers with classical PKU have microcephaly, mental retardation, and/or congenital heart defects. They have a transient elevation of phenylalanine (240-1200 µM) which falls to normal within 24 hours. A screening test on the mothers of infants with transient hyper-phenylalaninemia, particularly if the infant’s sample was collected in the first 24 hours after birth is recommended. Phenylalanine restricted diet begun prior to conception and during pregnancy can often prevent damage to the fetus.
Laboratory Tests

PKU and hyperphenylalaninemia are detected using tandem mass spectrometry (MS/MS); the normal phenylalanine level is < 200 µM.

Treatment

With proper treatment, mental retardation is totally preventable. Treatment should be started as soon after birth as possible (certainly before 3 weeks of age) in any infant recommended for treatment by the consultants and should be continued indefinitely. Frequent monitoring is required, especially in the first weeks, because variant forms of hyperphenylalaninemia may be indistinguishable from true PKU and improper nutritional therapy can be fatal.

If treatment is not started for some weeks, the results are more variable and the I.Q. tends to be lower. Patients whose treatment begins after six months are likely to remain mentally retarded. Older patients usually show little change in I.Q. with treatment, but a low phenylalanine diet may help to control serious behavior problems.

Screening Practice Considerations

Detection may depend on the amount of protein ingested or endogenously produced by the infant, but most affected babies (90 percent) have abnormal results even in the first 24 hours of life regardless of intake. Those with milder forms of hyperphenylalaninemia require longer periods of feeding or catabolism to develop abnormal tests.

If an infant is tested < 48 hours of age, a repeat test must be done after two but before 15 days of age (see Timing, page 32).

Contamination of the filter paper with food, or liquids containing NutraSweet (Aspartame) may cause false positive results or inadequate specimen.

<table>
<thead>
<tr>
<th>RESULTS</th>
<th>LIKELY CAUSES</th>
<th>ACTIONS</th>
</tr>
</thead>
</table>
| Phenylalanine ≥200 µM, Phe/Tyr ≥3.0 µM | * PKU possible  
* Variants forms of PKU  
* Mother has PKU  
* False positive  
* Transient hyperphenylalaninemia | Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail. |

The purpose of newborn screening is to identify infants at risk and in need of more definitive testing. As with any laboratory test, both false negative and false positive results are possible. Screening test results are insufficient information on which to base diagnosis or treatment.
TYROSINEMIA

Elevated tyrosine may result from several inherited defects of tyrosine catabolism, delayed maturation of enzymes or liver disease.

Transient Tyrosinemia

Transient tyrosinemia of the newborn is common (1:1,000) and more common among Inuit and Eskimo populations in Alaska. Transient tyrosinemia is thought to arise from delayed maturation of the liver enzyme, 4-hydroxyphenylpyruvic acid dehydrogenase (4HPPD), coupled with increased protein intake and/or occult ascorbic acid deficiency. Tyrosine levels may be quite high (>500 µM) peaking at 14 days of life and resolved by one month. Premature infants may have prolonged hypertyrosinemia.

Clinical Features

Transient tyrosinemia of the newborn may present with lethargy or decreased motor activity, but is usually a biochemical abnormality found in an otherwise normal newborn. For normal newborns transient tyrosinemia is not associated with long term sequela, although this has not been systematically studied.

Treatment

Transient tyrosinemia, while probably benign, may in some cases be treated with protein restriction to 2g/kg/day and administration of ascorbic acid (50-200 mg/day orally for 1-2 weeks) to infants found to have elevated tyrosine. If the infant is breast feeding, ascorbic acid alone may be administered.

Hepatorenal Tyrosinemia

Tyrosinemia, Type I or fumarylacetoacetate hydrolase (FAH) deficiency occurs in 1:100,000 births. Hepatorenal tyrosinemia is inherited as an autosomal recessive trait.

Clinical Features

Tyrosinemia, Type I causes severe liver and renal disease and peripheral nerve damage. Presentation in infancy includes vomiting, lethargy, diarrhea and failure to thrive. Liver disease with hepatomegaly, hypoproteinemia, hyperbilirubinemia, hypoglycemia and coagulopathy may be present. In an international survey of 108 patients, 13% (n=14) became symptomatic in the first two weeks of life and 36% (n=39) in the first two months. Renal proximal tubular dysfunction results in aminoaciduria, hyperphosphaturia and hypophosphotemic rickets. Untreated, death in infancy or childhood from acute liver failure, neurological crises, or hepatocellular carcinoma is usual.

Treatment

Therapy with NTBC [2-(nitro-4-trifluoromethyl-benzoyl)-1-3-cyclohexanedione]blocks the formation of the toxic metabolites. NTBC is effective in preventing or halting liver and renal damage and averting acute neurological crises. Long term outcome of NTBC therapy on the development of hepatic carcinoma is yet unknown. Liver transplantation may be used in selected cases. Adjunct therapy with dietary restriction of phenylalanine and tyrosine as well as symptomatic treatment of clotting defects, rickets and proximal tubular losses may also be indicated.

Occulocutaneous Tyrosinemia

Tyrosinemia, Type II is caused by a deficiency of the enzyme tyrosine aminotransferase (TAT) and is inherited as an autosomal recessive trait. TAT deficiency is rare, with about 50 cases described worldwide.

Clinical Features

TAT is manifested primarily in the eyes, the skin and the central nervous system. In the eyes, tyrosine crystals accumulate, resulting in painful corneal erosions. Equally painful hyperkeratotic plaques develop on the plantar surfaces of hands, feet and digits. Symptoms usually develop in the first year of life, but have been present on the first day of life or not occur until adulthood. A variable degree of mental retardation is present in about 50% of cases.
Treatment
A diet restricting phenylalanine and tyrosine is effective in clearing and/or preventing ulcerations.

Laboratory Tests
Tyrosinemia is detected using MS/MS; the cutoff tyrosine level is <475 µM. There is considerable overlap in tyrosine levels between normal infants, those with transient tyrosinemia and affected infants, making the tyrosine level itself not very specific. Clinical correlation, blood amino acids and urine succinylacetone are necessary to differentiate these cases.

Screening Practice Considerations
Tyrosine may be slow to rise in affected infants, making it more likely to be found on routine second testing. Practitioners must remain alert to the possibility of tyrosinemia in any infant with liver disease, corneal or keratotic lesions.

<table>
<thead>
<tr>
<th>RESULTS</th>
<th>LIKELY CAUSES</th>
<th>ACTIONS</th>
</tr>
</thead>
</table>
| Tyrosine ≥ 475 µM| * Transient Tyrosinemia  
* Tyrosinemia possible  
* Liver disease  
* Hyperalimentation  
* False Positive | Lab phones results to consultants, who phone practitioner with follow up recommendations. Notification is followed up by mail. |
ORGANIC ACIDEMIAS

Organic acidemias (OA) result from enzyme deficiencies involved in the catabolism of multiple amino acids and other metabolites. Maple syrup urine disease is detected by an elevation of the amino acid leucine and an abnormal leucine/alanine ratio. All the other OAs are detected through elevations in acylcarnitines. All have autosomal recessive inheritance and collectively have an incidence of 1:53,000. The following OAs are screened for by MS/MS:

- Beta-ketothiolase deficiency
- Glutaric acidemia, Type 1 (glutaryl-CoA dehydrogenase deficiency)
- Isobutyryl CoA dehydrogenase deficiency
- Isovaleric acidemia, (isovaleryl-CoA dehydrogenase deficiency)
- Malonic aciduria
- Maple Syrup Urine Disease (branched chain alpha-ketoacid dehydrogenase deficiency)
- Methylmalonic acidemias, methylmalonyl CoA mutase deficiency and 5 defects of B12 metabolism
- Propionic acidemia
- 3-Hydroxy-3-methylglutaryl (HMG) CoA lyase deficiency
- 2-Methyl-3-hydroxybutyryl CoA dehydrogenase deficiency
- 2-Methylbutyryl CoA dehydrogenase deficiency (mitochondrial acetoacetyl-CoA thiolase deficiency)
- 3-Methylcrotonyl CoA carboxylase (3MCC) deficiency
- 3-Methylglutaconyl CoA hydratase deficiency (3-methyl-glutaconic aciduria, Type 1)
- Multiple carboxylase deficiency

Clinical Features

**Neonatal Onset:** Most of these disorders have severe forms that present in the first week of life and constitute a neonatal emergency. Infants are generally well at birth, but develop poor feeding, irritability, lethargy, vomiting, and severe metabolic ketoacidosis, with or without hypoglycemia, in the first few days of life; this progresses to coma and death in the first month if treatment is not instituted. In methylmalonic and propionic acidemias, ammonia may also be elevated. Isovaleric acidemia is also associated with the odor of “sweaty socks.” Maple Syrup Urine Disease has a characteristic “burnt sugar” or “maple syrup” odor which can be noticed in the urine, sweat and ear cerumen of the affected infant as early as the fifth day of life. Isobutyryl CoA dehydrogenase deficiency is associated with a dilated cardiomyopathy. Even with prompt treatment, many infants with neonatal forms of organic acidemias sustain psychomotor damage and may have significant long term morbidity. These infants may be ill before the results of the screening tests are known.

**Late Onset:** Milder variants may present with an acute decompensation brought on by an intercurrent illness similar to those described above, or with failure to thrive, hypotonia mental retardation and a history of bouts of vomiting, protein intolerance, acidosis and/or hypoglycemia. While these patients typically have ‘milder’ disease, the neurological damage may be just as severe as those presenting earlier. Newborn screening may be very beneficial to these infants as the initial crisis may be prevented.

**Asymptomatic Cases:** There are numerous reports of cases of isolated 3-methylcrotonyl-CoA carboxylase deficiency who have remained asymptomatic despite biochemical and/or enzymatic confirmation of the condition. The etiology of these variant presentations is not yet understood.

**Glutaric Acidemia, Type 1:** Glutaric acidemia, Type 1 or GA1 is an organic acidemia with clinical features unlike those described above. In this disease, there is an accumulation of glutaric acid and 3-hydroxy glutaric acid, which are believed to be toxic to cells, particularly in the central nervous system. The classic presentation is macrocephaly at or shortly after birth. Infants have a period of apparently normal development but may have soft neurological signs, like jitteriness, irritability and truncal hypotonia. Generally between 6 and 18 months of age, patients will experience an acute encephalopathic episode resulting in damage to the basal ganglia and
atrophy of the caudate and putamen. Severe dystonia, dyskinesia and other neurological findings result, either in a static or slowly progressive form. These children are often misdiagnosed as having extrapyramidal cerebral palsy. Approximately 25% of GA1 patients will present with motor delay, hypotonia, dystonia and dyskinesia that develop gradually during the first few years of life, without any apparent acute crisis. Intellect is relatively intact. Infants with GA1 are prone to acute subdural and retinal hemorrhages, after minor head trauma. This can be misdiagnosed as child abuse. Finally, five percent of all Amish patients have been completely asymptomatic without any crises and normal development. Neurological crises and symptoms rarely occur after five years of age.

**Laboratory Tests**

All these disorders are detected by MS/MS. Leucine can be elevated in infants receiving hyperalimentation, usually along with other amino acid elevations. In a normal newborn, however, elevations of these compounds are unusual and require rapid follow up.

<table>
<thead>
<tr>
<th>RESULT</th>
<th>LIKELY CAUSES</th>
<th>ACTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leucine &gt; 300 µM Leu/ala &gt;1.75</td>
<td>* MSUD possible  * Hyperalimentation  * False positive</td>
<td>Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail.</td>
</tr>
<tr>
<td>C3 (Propionyl) &gt;10.0 µM</td>
<td>* Methylmalonic acidemias possible  * Multiple carboxylase deficiency possible  * Propionic acidemia possible  * False positive</td>
<td>Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail.</td>
</tr>
<tr>
<td>C3 (DC Malonyl) &gt;1.9 µM</td>
<td>* Malonic aciduria possible  * False positive</td>
<td>Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail.</td>
</tr>
<tr>
<td>C4 (Butyryl) &gt;2.3 µM</td>
<td>* Isobutyryl CoA dehydrogenase deficiency possible  * False positive</td>
<td>Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail.</td>
</tr>
<tr>
<td>C4-DC (Methylmalonyl) &gt;1.6 µM</td>
<td>* Methylmalonic acidemias possible  * False positive</td>
<td>Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail.</td>
</tr>
<tr>
<td>C5 (Isovaleryl) &gt;1.0 µM</td>
<td>* Isovaleric acidemia possible  * 2-Methylbutyryl CoA dehydrogenase deficiency possible  * False positive</td>
<td>Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail.</td>
</tr>
<tr>
<td>C5-DC (Glutaryl) &gt;1.7 µM</td>
<td>* Glutaric acidemia, Type 1 possible  * False positive</td>
<td>Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail.</td>
</tr>
</tbody>
</table>

(table continued on next page)
The purpose of newborn screening is to identify infants at risk and in need of more definitive testing. As with any laboratory test, both false negative and false positive results are possible. Screening test results are insufficient information on which to base diagnosis or treatment.
FATTY ACID OXIDATION (FAO) DISORDERS

Mitochondrial beta-oxidation of fatty acids is crucially important in the body’s ability to produce energy, particularly during fasting. In infants, a “fasting” state can be produced in as little as 4 hours. Fatty acids must be transported into the cytoplasm and then into the mitochondria for oxidation; carnitine is required for these transport steps. Once in the mitochondria, fatty acid chains 4-18 carbons in length must be oxidized, 2 carbons at a time, each reaction using a chain-specific enzyme, before ketogenesis can occur. There are over 20 individual steps in beta-oxidation some with multiple enzyme complexes. An enzyme block anywhere in this process or a carnitine deficiency will result in hypoketotic hypoglycemia and tissue damage related to the toxic accumulation of unoxidized fatty acids. At least 16 separate enzyme disorders have been identified, many of which may be identified by MS/MS by measuring the accumulation of various acylcarnitines.

**Fatty acid oxidation disorders**
- Carnitine transport defect (enzyme unknown)
- Carnitine/acylcarnitine translocase (CT) deficiency
- Carnitine palmitoyl transferase (CPTI) deficiency
- Carnitine palmitoyl transferase II (CPTII) deficiency
- Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency
- Long chain L-3 hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency
- Medium chain acyl-CoA dehydrogenase (MCAD) deficiency
- Short chain acyl-CoA dehydrogenase (SCAD) deficiency
- Multiple acyl-CoA dehydrogenase deficiency (MADD aka GA 2)
- Trifunctional protein (TFP) deficiency

MCAD is the most common, approximately 1:10,000 births; LCHAD is less frequent, but not rare. The true incidence of the other disorders is unknown. All are inherited as autosomal recessive traits.

**Clinical Features**

FAO disorders have overlapping symptoms and organ involvement. They fall into three major categories as described below.

**Hepatic:** There is no typical age of presentation, which may be on the first day of life through adulthood. Precipitating factors are fasting and/or stress associated with intercurrent illness. Patients present with “Reyes-like” symptoms including vomiting, lethargy, hypoketotic hypoglycemia, mild hyperammonemia, hyperuricemia, hypocarnitinemia and abnormal liver function tests. Liver biopsy often shows steatosis. Hepatic presentation is common in MCAD, VLCAD, LCHAD, neonatal CPT I & II and mild CT deficiency. Approximately 25 percent of individuals with MCAD will die during their first episode. In survivors, about 20 percent sustain significant neurological damage, presumably due to hypoglycemia. Patients with LCHAD also develop retinal pigmentary changes and progressive visual loss.

**Cardiac:** Cardiac abnormalities include hypertrophic or dilated cardiomyopathy. Pericardial effusion or cardiac failure can lead to death in these patients. FAO disorders with cardiac involvement include carnitine transporter defects, LCHAD, TFP deficiency, neonatal CPT II and VLCAD.

**Muscle:** There is usually moderate to severe hypotonia with recurrent rhabdomyolysis. Creatinine kinase may be greatly elevated. In infants and children seizures and/or developmental delay may also be present. Rhabdomyolysis is common in the adult form of CPT II, LCHAD, TFP deficiency and VLCAD.

---

*These are not all the FAO disorders, only the ones thought to be detectable with MS/MS. At this time the sensitivity and specificity of MS/MS to detect all affected infants is unknown.*
Mothers carrying an affected LCHAD fetus are prone to developing life threatening acute fatty liver of pregnancy or HELLP syndrome (hemolysis, elevated liver enzymes, low platelets). The reasons for this are not yet understood, but FAO disorders should be considered in children whose mothers have a history of these pregnancy complications.

**Treatment**

Even with screening, some infants with FAO disorders may die before results are available. Treatment for MCAD and some other FAOs is extraordinarily simple once the diagnosis is suspected. Avoidance of fasting, particularly as infants and young children, is the primary treatment. Carnitine supplementation (100mg/kg/day) is used to provide a pathway for removal of toxic intermediate metabolites in some FAOs. With appropriate treatment hepatic, cardiac and muscle complications can be reduced or eliminated. Patients with these disorders may require IV support for fluid and calories during intercurrent infections or illnesses. With pre-symptomatic diagnosis and appropriate therapy, outcome can be normal for MCAD. Outcome for the other disorders is unknown.

**Screening Practice Considerations**

Neonatal forms of FAO disorders can present in the first few days of life. Collect specimens at discharge or between 48-72 hours. Transport within four to six hours of collection and no later than 24 hours after collection. Practitioners must remain alert to the possibility of FAO disorders in any neonate, infant or child with hypoketotic hypoglycemia or “Reyes-like” episodes.
The purpose of newborn screening is to identify infants at risk and in need of more definitive testing. As with any laboratory test, both false negative and false positive results are possible. Screening test results are insufficient information on which to base diagnosis or treatment.

<table>
<thead>
<tr>
<th>RESULTS</th>
<th>LIKELY CAUSES</th>
<th>ACTIONS</th>
</tr>
</thead>
</table>
| CO (free carnitine) <7.0 µM | * Carnitine transport defects possible  
* Carnitine deficiency  
* False | Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail. |
| C14 (Tetradecanoyl) > 1.0 µM  
C14:1 (Tetradecenoyl) > 1.4 µM  
C16 (Palmitoyl) > 9.7 µM | * VLCAD possible  
* False positive | Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail. |
| C16 (Palmitoyl) > 9.7 µM | * LCHAD, VLCAD, CPT II, CT deficiencies possible  
* False positive | Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail. |
| C16-OH (Hydroxy Palmitoyl) > 1.1 µM | * LCHAD, TFP possible  
* False positive | Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail. |
| C6 (Hexanoyl) > 0.9 µM  
C8 (Octanoyl) > 1.0 µM  
C10:1 (Decenoyl) > 0.8 µM | * MCAD possible  
* False positive | Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail. |
| C4 (Butyryl/Isobutyryl) > 1.6 µM | * SCAD possible  
* False positive | Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail. |
| C4 > 1.6 µM  
C5 > 1.0 µM  
C5-DC > 1.7 µM  
C6 > 1.0 µM  
C8 > 0.9 µM  
C10 > 0.9 µM  
C16 > 9.7 µM | * MADD/GA II possible  
* False positive | Lab phones results to consultants, who phone practitioner with recommendation. Notification is followed up by mail. |
SCREENING PRACTICES

Definition
SCREENING PRACTICES are the actions and decisions of practitioners regarding the collection, handling and follow-up of newborn screening specimens. Over 30 percent of cases of PKU and hypothyroidism missed by screening programs are due to errors in screening practice.

Who Is Responsible For Ensuring That The Screening Test Is Performed?
Alaska Statute and Administrative Code requires that every baby be tested, and designates practitioners as being responsible for specimen collection. The definition of “practitioner” includes physicians, nurses, and lay midwives who deliver or care for infants in hospitals, birth centers or at home. If no practitioner is present, it is the parents’ responsibility to have the baby tested. All infants must be tested prior to hospital discharge.

Parent Refusal To Have The Baby Tested
The parent may refuse testing for religious beliefs. However, it is the responsibility of the practitioner to obtain a signed Informed Dissent document and ensure that it is placed in the infant’s medical record. Failure to do so may result in practitioner liability if an affected infant is not screened. Sample statements of parental religious exemption are given on page 42.

Proper Time For Testing
A specimen obtained prior to 48 hours of age is valid for most of the conditions covered on the newborn screening battery. There is, however, a statistical chance that aminoacidopathies like PKU may be missed. In Alaska, six percent of all infants with PKU and 10 percent of those with hypothyroidism are found only on the second specimen.
To clarify testing guidelines, Alaska regulations require discharge testing. If the specimen is obtained prior to 48 hours of age or the infant is pre-term, the infant must have a second test prior to 21 days of age.

Percentage of Affected Infants Identified by Routine First and Second Screening Tests in the NWRNBSP

<table>
<thead>
<tr>
<th>DISORDER</th>
<th>FIRST TEST</th>
<th>SECOND TEST</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobinopathies</td>
<td>&gt;99%</td>
<td>NA</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>90%</td>
<td>10%</td>
</tr>
<tr>
<td>Congenital Adrenal Hyperplasia</td>
<td>95%</td>
<td>5%</td>
</tr>
<tr>
<td>Phenylketonuria</td>
<td>&gt;94%</td>
<td>6%</td>
</tr>
<tr>
<td>MSUD</td>
<td>&gt;99%</td>
<td>1%</td>
</tr>
<tr>
<td>Other Amino Acidopathies</td>
<td>50-90%</td>
<td>10-50%</td>
</tr>
<tr>
<td>Galactosemia</td>
<td>99%</td>
<td>1%</td>
</tr>
<tr>
<td>Biotinidase Deficiency</td>
<td>100%</td>
<td>0%</td>
</tr>
<tr>
<td>Fatty Acid Oxidation Disorders</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Testing Before Discharge
The law specifies that infants must be tested before discharge from the birthing unit, regardless of the age or feeding status. This is done because some infants do

<table>
<thead>
<tr>
<th>SPECIMEN TIMING</th>
</tr>
</thead>
<tbody>
<tr>
<td>“Early Testing”</td>
</tr>
<tr>
<td>“Standard Test”</td>
</tr>
<tr>
<td>If 1st sample is obtained:</td>
</tr>
<tr>
<td>≤48 hours</td>
</tr>
<tr>
<td>&gt;48 hours-5 days</td>
</tr>
<tr>
<td>then 2nd sample should be obtained</td>
</tr>
<tr>
<td>5-15 days</td>
</tr>
<tr>
<td>15 days-until collected**</td>
</tr>
<tr>
<td>2nd sample is not required if taken by these guidelines</td>
</tr>
</tbody>
</table>

** In any case, a specimen obtained outside the recommended guidelines is preferred over an infant having no specimen or repeat at all.
not return for routine post-natal care and most of the tests are valid at any age. Failure to collect a specimen before discharge may confer a significant liability on both the facility and responsible practitioner if an affected infant is missed as evidenced by published case law. It is best to obtain the first test as close to discharge as possible for normal newborns, i.e., 24–48 hours of age. Hospitals are sent double test cards. One card is used for the discharge test, the second for the repeat sample. It is critical that the cards be used in the proper order.

**Testing Before Transfer Of Infant To Another Unit**

Alaska Administrative Code specify that infants who are transferred to another unit within 48 hours of birth should be tested by the receiving facility. Infants who are transferred after 48 hours must have a blood sample collected before transfer.

**Patient Demographic Information**

Be sure to use the correct part of the kit: **PART 1** for the first test and **PART 2** for the second test. Failure to do so makes it difficult to track the infant’s results. In addition, hemoglobin testing is only done on the first specimen. The laboratory form should be completed with the information requested; it is part of the legal record and must be legible. Infant’s name, birth date, specimen date and physician's name are particularly important. It is also important to indicate what kind of food the infant has received prior to testing. Patient information is critical for rapid follow-up in the event of abnormal results. Do not use plastic imprint cards, as they often produce unreadable information and cause compression damage to the filter paper.

**Special Transport**

It is critically important that newborn screening specimens are received by the laboratory as soon as possible after collection. Ideally specimens should be mailed or transported as soon as they are dried (four to six hours) and no later than 24 hours after collection. Many of the conditions on the screening battery kill or maim infants in the first week of life. To prevent this, diagnosis and treatment must occur rapidly. Consideration should be given to the use of overnight courier or mail services if specimens are taking longer than two or three days to arrive at the laboratory. Significant degradation of hemoglobin and some analytes can occur in specimens older than one week.

If a courier is used, it is advisable to establish a list of specimens sent and to document the time of specimen pickup. This protects the submitter if specimens are lost in transit.

**Special Considerations**

**Premature Or Sick Infants** Infants who are premature or sick should have the first test collected between five and seven days. Remember that T4 results may be quite low in normal premature infants.

Many intensive care nurseries obtain an initial screening specimen on all infants on admission to avoid these problems.

**Hyperalimentation And Antibiotic Therapy**

These are not contraindications to testing, but samples should not be taken from the line which is used to deliver the alimentation or drugs. High levels of several amino acids can occur during hyperalimentation. Antibiotics containing pivalic acid given to mothers during labor or newborns may cause a false elevation of isovaleryl/2-methylbutyryl. Be sure to specify these therapies on the request slip.

**Transfusions** A specimen should be obtained before the transfusion, as donor cells provide normal levels of enzymes and hemoglobins. Metabolite tests (e.g., PKU, MSUD, galactosemia) will become abnormal after feedings are begun, regardless of the transfusion. If an infant is not screened prior to transfusion, obtain a specimen from the blood drawn for typing and cross matching if possible. Be sure to specify this on the request slip.

Specimens for infants screened after a transfusion may take as long as 120 days to become abnormal, significantly delaying diagnosis and treatment. Many intensive care nurseries obtain an initial screening specimen on all infants on admission to avoid these problems.
Clinical Signs or Family History

There are a number of clinical situations that will modify the usual approach of obtaining a newborn screening specimen and waiting for the result. The following are brief suggested guidelines for particular situations that may arise in clinical practice. Regardless of any diagnostic or therapeutic interventions, a newborn screen should be obtained on all infants, to test for the other conditions included in the panel.

When in doubt about the course of management for any of the conditions on the screening test, consultation with a specialist is advised.

- Newborn Screening of an Infant Who Exhibits Clinical Signs and Symptoms
The newborn screening test, like any laboratory test, may have false positives and false negatives. If signs and symptoms of one of the newborn screen conditions are clinically evident, the physician should proceed to diagnostic testing, pending the results of the screen or in spite of the results of the screen. It may be necessary to **treat as if the infant has the condition**. 24-hour medical consultation is available for assistance with rapid diagnosis and institution of treatment for infants suspected to have disease.

- If the newborn screening test result was “normal”:
If clinical symptoms suggest one of the screened conditions despite a “normal” screening test, the physician should **proceed as if the patient has the condition** and immediately contact a consultant specialist for instructions on further evaluation of the patient.

- Newborn Screening of an Infant with an Affected Sibling or Other Close Relative
As many of the conditions tested for by newborn screening are genetic, it is possible that multiple members of a family may be affected. Prenatal diagnosis is possible for many of these conditions; if prenatal diagnosis determines that the infant is affected, any appropriate treatment (e.g., special diet) should be initiated immediately after birth. If prenatal diagnosis predicts an unaffected baby, practitioners should bear in mind that no prenatal diagnostic test is 100% accurate. Neonates who are siblings or close relatives of an affected individual are not part of the “general population” for whom newborn screening is designed. For any infant with a positive family history, providers should contact appropriate consultant specialists, ideally prenatally, or immediately at birth, to determine the proper diagnostic tests and proper timing of those tests.

Consultation with a specialist is usually necessary and always recommended in these situations. The directory on pages 1 and 2 offers consultants by disease for your state to assist with screening and confirmation testing.
Specimen Collection

1. To prevent specimen contamination, do not touch any part of the filter paper circles before, during or after collection. Disposable gloves and lactose residue from gloves or sweat/oils from fingers can contaminate the specimen.

2. Hold infant’s limb lower than the heart, warm if necessary with water or a warm towel. Heat pack should not exceed 42°C and should not be left in contact with skin for a prolonged period.

3. Select a puncture site on the heel (see diagram) and cleanse with alcohol (not iodine), air dry. Cord blood is not a satisfactory specimen. Samples obtained from peripheral or central line are acceptable, provided that the line is not being used for hyperalimentation or for antibiotics.

4. Puncture the heel with the sterile lancet to the full length of the blade. Wipe away the first drop of blood to remove tissue fluids. Sufficient blood should collect on the heel to fill each circle by a single application of paper to a drop of blood. Apply only from one side of the filter paper. Blood should soak all the way through the paper such that the blood spots look similar on both sides. Complete saturation of the entire circle is essential for accurate testing.

5. It is important not to superimpose the blood drops on top of each other. Let each drop touch the paper about 1/8 inch away from the previous one. This prevents layering of the paper, which is one cause of false results.

6. Collect the blood in all four circles. A minimum of three circles is necessary to complete the test battery. If there are problems obtaining an adequate quantity of blood, it is better to fill three circles completely, than to fill four circles inadequately.

7. After blood has been collected, the foot should be elevated above the body, and a sterile gauze pad or cotton swab pressed against the puncture site until the bleeding stops.

8. Air dry specimens at room temperature for 2-4 hours in a horizontal position. Do not dry on a heater or in a microwave. Ensure that sample is completely dry before mailing.

9. Insert dried sample into envelope (do not use plastic), seal and mail. If sample(s) cannot be mailed because of a Sunday or Monday holiday, it is better to store it in a cool room and send by express mail. All specimens should be mailed first class or express. Do not batch specimens collected on separate days. Do not put in a hot mailbox over the weekend.

Recommendation for Heel Puncture Site in Newborns

Perform punctures on the most medial or most lateral portion of the plantar surface of the heel (see diagram). Lancets longer than 2.4 mm should not be used on infants weighing less than 2500 g.

A full-color chart illustrating proper specimen collection, “Neonatal Screening Blood Specimen Collection and Handling Procedure,” may be obtained at no charge from Schleicher & Schuell, Inc., PO Box 2012, Keene, New Hampshire 03431; 800-245-4024; FAX 603-357-7700.

These instructions are consistent with the recommendations in Blood Collection on Filter Paper for Neonatal Screening Programs. National Committee for Clinical Laboratory Standards. Vol. 12 No. 13 1992 [NCCLS Document LA4-A2]
Unsatisfactory Specimens

Newborn screening laboratories receive many specimens that are unacceptable for testing. If the specimen is improperly collected, the accuracy of the screening test results is compromised, so the laboratory must reject them. This delays the screening of the newborn and requires that the submitter locate the infant and repeat the collection procedure.

The following table outlines the most common errors in specimen collection.

<table>
<thead>
<tr>
<th>INVALID SPECIMEN</th>
<th>POSSIBLE CAUSES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quantity of blood not sufficient for testing (QNS)</td>
<td>Filter paper circles incompletely filled or not saturated/not all circles filled.</td>
</tr>
<tr>
<td></td>
<td>Blood applied with needle or capillary tube.</td>
</tr>
<tr>
<td></td>
<td>Contamination of surface of filter paper circle before or after specimen collection by gloved or ungloved hands, or by substances such as hand lotion or powder, etc.</td>
</tr>
<tr>
<td>Blood spots appear scratched or abraded</td>
<td>Blood applied improperly using capillary tube or other means (blotter has been damaged or torn by device).</td>
</tr>
<tr>
<td>Blood spots wet</td>
<td>Specimen not properly dried before mailing.</td>
</tr>
<tr>
<td>Blood spots appear supersaturated</td>
<td>Excess blood applied (usually with capillary tube or needle).</td>
</tr>
<tr>
<td></td>
<td>Blood applied to both sides of filter paper.</td>
</tr>
<tr>
<td>Blood spots appear diluted, discolored, or contaminated</td>
<td>Puncture site squeezed or “milked.”</td>
</tr>
<tr>
<td></td>
<td>Exposure of blood spots to direct heat.</td>
</tr>
<tr>
<td></td>
<td>Contamination of filter paper before or after specimen collection by gloved or ungloved hands, or by substances such as alcohol, formula, water, powder, antiseptic solutions, or hand lotion.</td>
</tr>
<tr>
<td></td>
<td>Contamination during transit.</td>
</tr>
<tr>
<td>Blood spots exhibit “serum rings”</td>
<td>Alcohol not wiped off puncture site before skin puncture is made.</td>
</tr>
<tr>
<td></td>
<td>Filter paper has come into contact with alcohol, water, hand lotion, etc.</td>
</tr>
<tr>
<td></td>
<td>Puncture site squeezed excessively.</td>
</tr>
<tr>
<td></td>
<td>Specimen dried improperly.</td>
</tr>
<tr>
<td></td>
<td>Blood applied to the filter paper with a capillary tube.</td>
</tr>
<tr>
<td>Blood spots appear clotted or layered</td>
<td>Same filter paper circle touched to a blood drop several times.</td>
</tr>
<tr>
<td></td>
<td>Circle filled from both sides of the filter paper.</td>
</tr>
<tr>
<td>Blood will not elute from the blotter paper</td>
<td>Blood specimen has been heat-fixed.</td>
</tr>
<tr>
<td></td>
<td>Blood specimen is too old (more than two weeks between collection and receipt by the screening laboratory).</td>
</tr>
</tbody>
</table>

Consult the state screening lab for additional information and assistance with specimen collection.

A full-color chart illustrating invalid specimens and their causes, “Simple Spot Check,” may be obtained at no charge from Schleicher & Schuell, Inc., PO Box 2012 Keene, New Hampshire 03431; 800-245-4024; FAX 603-357-7700.
REPORTING OF RESULTS

Practitioner Responsibility For Documentation

It is the responsibility of the practitioner to ensure every baby is tested and that a result is received and filed in the medical record. Practitioners should know the screening status of every infant in their care, regardless of age. Specimen collection must be documented in the infant’s chart and, if preferred, in a separate log book. Information should include name of infant, hospital ID number, screening kit ID number, date collected, date mailed and the name of the person who collected the specimen. When screening results are returned to the submitter they should be noted in the log book and the report filed in the medical records. Private practitioners must also ensure that the second specimen is obtained at the appropriate time and that documentation is completed.

In the event that the results of an infant’s screening tests are not received from the Screening Laboratory within two weeks after collection, the hospital and practitioner must assume responsibility for follow-up. We recommend the following procedure:

1. Contact the Oregon State Public Health Laboratory, Newborn Screening Section, Leanne Rien, RN, Coordinator, (503) 229-5466 or Alaska Division of Health Care Services, Thalia Wood, Newborn Screening Program Manager, (907) 269-3499, to determine if the specimen was received and to request a report to be mailed or faxed.
2. If the specimen was not received, it must be presumed lost. Notify the infant’s private physician, local health nurse or parents by phone or letter that the specimen may have been lost and that another should be obtained without delay.
3. Document these actions in the infant’s medical record.
4. Request a copy of screening results to be sent to your facility for the medical record.
5. If these steps do not result in the infant being screened, notify Leanne Rien, RN, or State of Alaska, Division of Health Care Services, State Program Manager at (907) 269-3499.

Normal Results

Normal results are mailed daily to submitters. The complete test battery is usually completed in two to ten working days after receipt by the laboratory.

“Significant” Abnormal Results

All results considered urgent are reported to the medical consultants who will phone submitting hospital or practitioners with recommendations for further action. Such action is followed by mail or fax confirmation.

Before discharge, hospital and birth unit personnel may be designated and listed on the request slip as the physician-of-record. In the event of an abnormality, the screening laboratory will refer to the physician-of-record although the infant is no longer under his or her care and may not even be known to them. Responsibility for follow-up remains with the physician of record until it is actively accepted by another practitioner.

“Other Abnormal and Repeats”

Lesser abnormalities or inadequate samples are reported immediately by mail or fax to the submitting hospital and/or practitioner with a request for retesting.

It is the practitioner’s responsibility to ensure that all infant’s with abnormal results are retested, however all such infants are also tracked by the laboratory and/or the medical consultants until resolutions or a diagnosis is confirmed.

State health agencies are notified for assistance when there are problems in obtaining repeat tests for infants with abnormal results.
PROBLEMS IN SCREENING PRACTICE

Infants Who Are Never Tested
In the United States, for every one percent of infants who are not tested, three cases of PKU and ten cases of hypothyroidism are likely to be missed each year. These infants represent a major medical and legal liability to the program and to practitioners involved in their care. The legal awards for missed cases have been as high as $30 million/case. Special attention should be given for older infants not born in the US (i.e., adopted and/or migrant).

Parents’ Refusal To Have The Baby Tested
See page 32 for guidelines, and page 42 for an example of form to use in this situation.

Common Misconceptions
Failure to test a baby is often due to misconceptions about the program or the tests. For example, some practitioners believe the diseases are so rare they advise parents not to have the testing done. Approximately 50-100 infants/year are identified with one of the conditions described in this manual in the five state Region. Others believe the first test is of no value if obtained before 48 hours of age. Over 85 percent of affected infants have abnormal results on the first test regardless of age or food ingestion. See table on page 32.

Timing Of The Tests
High rates of early discharge and home delivery make this the most difficult problem in newborn screening. Timing recommendations are clear. Legal regulations concerning timing of first and second specimens are clearly stated in Alaska Administrative Code, which is updated at the advice of the Newborn Metabolic Screening Advisory Committee, to reflect national practices and standards of care.

Remember that 10 percent of all cases of hypothyroidism are detected from the second sample, with a normal first sample.

Specimen Inadequacy
Less than one percent of samples submitted to the laboratory contain insufficient blood to do all the tests or are contaminated with milk, stool or urine. This generates an automatic request for a retest and delays the testing.

Samples which are heated during drying or mailing may be damaged so that some tests are invalid.

Inadequate Demographic Information
Five percent of specimens are missing key patient data. For example, the specimen does not list the infant’s name, or it is unreadable. In the event of an abnormal result, these specimens are difficult and time consuming to match to the correct infant, especially in large facilities. The most common cause for unreadable specimens is illegible hand writing. It is important to write clearly and neatly. Data which are critical include: name, birthdate/hour, sample date/hour, feeding status, mother’s name, as well as practitioner name.

Problems Related To Specimen Transport To The Laboratory
All specimens should be transported as soon as they are dry and no later than 24 hours after collection. They should be received by the central laboratory no later than five days after collection. While some delays are due to unavoidable postal delays such as holidays, most are caused by failure to mail the samples promptly. Samples may be delayed because of sluggish in-house mail, inefficient courier services or simple forgetfulness, but perhaps the most dangerous practice is “batch mailing”, when samples are held up to a week so postage costs can be reduced.

Specimens collected on Sundays or Monday holidays are best stored in a cool room and sent express mail at the first opportunity.

The importance of early sample collection and prompt transit is illustrated by the fact that babies with galactosemia, organic acidemias and fatty acid oxidation disorders may die within a week or two of birth. Enzyme activity and hemoglobin may be destroyed or diminished in specimens which are older than 10 days or which have been exposed to heat and humidity. Prompt mailing is as important as early testing.
EDUCATIONAL SERVICES

Screening Practice Surveillance Program

In an effort to assist hospitals, birth facilities, and individual practitioners, the laboratory monitors the screening practices (transit time, inadequate specimens, demographic omissions and timing errors). Screening Practice Profiles are provided on a quarterly basis to hospitals and birth facilities in Alaska.

Birth Facilities, Health Departments, And Community Practitioners

1. Inservices can be provided at your facility by program staff. These presentations cover any (or all) aspects of the screening program.
2. Policy development and/or review. We are available to assist administrators and/or practitioners in the drafting of sound screening policies and procedures based on State laws, administrative rules as well as recommendations of the American Academy of Pediatrics and the National Committee for Clinical Laboratory Standards. This can be done in conjunction with inservice sessions or by mail or phone.
3. Video tape demonstrations showing correct collection procedures, complaints, problems and questions; this 20 minute tape is available to borrow or purchase by contacting Thalia Wood, MPH at 907-269-3499.

Parents And Lay Public

1. Parent brochures are included with each kit order.

   There is no charge for any of these educational materials or services. For additional information please contact:

   Thalia Wood, MPH, CLS
   State of Alaska, Division of Health Care Services
   3601 C Street, Suite 934
   Anchorage, Alaska 99524
   907-269-3499
   FAX 907-269-3465
SCREENING KIT INFORMATION

Only a standardized, quality tested filter paper can be used for specimen submission (Schleicher and Schuell 903). Requests for kits must be made using a kit request form showing the quantity requested. Orders should be submitted to: State of Alaska, Health and Social Services, Division of Health Care Services, 3601 C Street, Suite 934, Anchorage, Alaska 99524, telephone 907-269-3499, or FAX 907-269-3465. Please allow 2-3 weeks for preparation and shipping. Kit orders and specimens are not to be sent by collect mail.

Type Of Kits
Hospitals and birthing facilities receive double kits with identical kit numbers, so that the first and second specimens can be easily matched. Health departments, clinics, and private practitioners may order double or single kits. Single kits should only be used when the second part of a double kit has been lost or damaged. Please note: all kits are precoded for the specific individual/facility; they must not be loaned to, or borrowed from, other facilities. To obtain uncoded kits (to replace lost kits or to deal with emergency situations), contact Leanne Rien, RN at (503) 229-5466 or Thalia Wood, MPH at (907) 269-3499.

Cost
There is no charge for test kits. The cost of newborn screening is $55.00 per infant. If the newborn screening test is abnormal, the laboratory or medical consultant may recommend confirmatory testing. Laboratory tests for diagnostic testing are included in the $55.00 screening fee, if samples are sent to the Oregon Laboratory or submitted to the reference laboratory used by the program.

Cost Of Diagnostic Tests For Confirmation Of Abnormal Screening Results
When diagnostic quantitative tests are requested by the laboratory or by the medical consultant for full evaluation of an infant considered likely to have one of the disorders, the costs of performing these will be absorbed by the program provided that the samples are properly handled and submitted to a laboratory approved by this program. Fees for tests which are not specifically requested, or which are sent to other laboratories will not be reimbursed.
EXEMPTIONS

Fees

In Alaska, no person is refused service because of the inability to pay the fee for testing. A practitioner or parent requesting exemption from fees must complete a statement on the back of the specimen form similar to the one shown below:

Statement of Fee Exemption

The undersigned states that the parents of _______________________________are unable to pay the fee for testing for Newborn Screening disorders because of lack of sufficient funds.

_________________________________________ ________________________
PARENT or PRACTITIONER   DATE

Alternatively the practitioner must provide a list of exempt infants which includes each infant’s name, birth date, the name of the parent or practitioner and date to the State of Alaska for billing purposes.

Religious Objections

A religious exemption can be claimed from the requirement for the newborn screening tests. In this event, the person otherwise responsible for submitting the specimen for testing is responsible for submitting a copy of the Informed Dissent form to the State Laboratory signed by the infant’s parent: see page 42.
PARENTAL REFUSAL

In the event a parent refuses the testing, the program strongly urges practitioners to obtain an “Informed Dissent” signed by the parent and placed in the infant’s medical record. Suggested wording is provided below:

NEWBORN SCREENING TEST REFUSAL

_______________________________ ____________________________________
Name of Infant Hospital of Birth

_______________________________ ____________________________________
Birth Date Street Address

_______________________________ ____________________________________
Medical Record Number City/State/Zip

I have been informed and understand that these tests are required by state law for all infants born in Alaska.
I have been informed and I understand that these tests are given to detect these disorders as symptoms may not appear for several weeks or months.
I have been informed and I understand that untreated, these conditions may cause permanent damage to my child, including serious mental retardation, growth failure and in some cases death.
I have discussed the testing requirements with ________________________________ and I have had explained, and I understand all the risks involved if these tests are not given to my child.
I have been informed and I understand the nature of the tests and how these tests are given.
I object to these tests and I do not want ________________________________tested for these conditions.
My decision was freely made without force or encouragement by my doctor, hospital personnel, or State officials.

Signed ________________________________ Relationship ________________________________
Witnessed by ___________________________ Date____/____/____

Original: Infant’s Medical Record Revised 9/1/02
Copies: Parent Practitioner Oregon State Public Health Laboratory
REPORTING REQUIREMENTS

The Alaska Newborn Screening Regulations require that hospitals, birthing facilities, or practitioners (out of hospital births) submit to the State of Alaska (Division of Health Care Services) a list of live births. This list may be sent or faxed to the state office and must include the infant’s name, birth date, sex, birth weight, and mother’s name (if different from the infant’s). The list is due each week and covers the same time period of the previous week. The names on this list are matched to the names on the newborn screening specimens by the Oregon Public Health Laboratory. A sample form is attached. (Information from the electronic birth certificates may be substituted for the form.) Hospitals are alerted by facsimile if an infant appears not to have been tested or the infant was tested but the sample was lost in transit.
LISTING OF LIVE BIRTHS

PURPOSE OF THIS REPORT: To assure that each newly born Alaskan is screened for medical disorders. This list will be computer matched to the Oregon Laboratory’s specimen list. If any of your births don’t have a matching specimen, you will be notified.

Birthing Service: ___________________________ Code#: AK___

From: ___________________________ Through: ___________________________
    Mo/Day/Year             Mo/Day/Year

Sender's Name/Department/Phone Number: ______________________________

INSTRUCTIONS:
1) Please type or print legibly.
2) Please omit stillbirths and neonatal deaths, unless you were able to obtain a specimen.
3) Use “comments” column to note name changes, transfers, etc.
4) Mail or FAX each Monday to: Newborn Screening Program
   PO Box 240249
   Anchorage, Alaska 99524
   907-269-3499 FAX: 907-269-3465

<table>
<thead>
<tr>
<th>INFANT’S NAME OR LAST NAME (as it appears on PKU Test Kit)</th>
<th>INFANT’S DATE OF BIRTH (Mo/Day/Yr)</th>
<th>INFANT’S SEX (M OR F)</th>
<th>INFANT’S BIRTHWEIGHT (lb-oz. preferred)</th>
<th>IF PARENTS REFUSED PKU</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ALASKA STATUTE AND REGULATIONS

Article 6. Phenylketonuria (PKU).

Section 200. Screening infants for phenylketonuria

Sec. 18.15.200. Screening infants for phenylketonuria.

(a) A physician who attends a newborn child shall cause this child to be tested for phenylketonuria (PKU). If the mother is delivered in the absence of a physician, the nurse who first visits the child shall cause this test to be performed.

(b) The Department of Health and Social Services shall prescribe regulations regarding the method used and the time or times of testing as accepted medical practice indicates.

(c) The necessary laboratory tests and the test materials, reporting forms and mailing cartons shall be provided by the department.

(d) All tests considered positive by the screening method shall be reported by the screening laboratory to the physician and to the department. The department shall provide services for the performance of a quantitative blood phenylalanine test or its equivalent for diagnostic purposes. A confirmed diagnosis of phenylketonuria shall be reported to the physician and to the department. The department shall provide services for treatment and clinical follow-up of any diagnosed case.

(e) When presumptive positive screening tests have been reported to the department, it shall provide, on request, either the true blood phenylalanine test or subsidize the performance of this test at an approved laboratory.

(f) A licensed physician or licensed nurse attending a newborn or infant who violates this section is guilty of a misdemeanor, and upon conviction is punishable by a fine of not more than $500. However, a person attending a newborn or infant whose request for appropriate specimens from the newborn or infant is denied by the parent or guardian is not guilty of a misdemeanor. The fact that a child has not been subjected to the test because a request for appropriate specimens has been denied by the parents or guardian shall be reported to the department. The department shall administer and provide services for testing for other heritable diseases which lead to mental retardation and physical handicaps as screening programs accepted by current medical practice and as developed.

(g) In this section, “physician” means a doctor of medicine licensed to practice medicine in this state, or an officer in the regular medical service of the armed forces of the United States or the United States Public Health Service assigned to duty in this state. (1 ch 90 SLA 1965; am 1 ch 39 SLA 1967; am 6 ch 104 SLA 1971)

Article 10. Screening of Newborn Children for Metabolic Disorders

<table>
<thead>
<tr>
<th>Section</th>
<th>Uniform standards</th>
</tr>
</thead>
<tbody>
<tr>
<td>510.</td>
<td>Persons required to collect specimens</td>
</tr>
<tr>
<td>520.</td>
<td>Collection of blood specimen</td>
</tr>
<tr>
<td>530.</td>
<td>Specimen collection materials</td>
</tr>
<tr>
<td>540.</td>
<td>Results of screening test</td>
</tr>
<tr>
<td>550.</td>
<td></td>
</tr>
</tbody>
</table>

7 AAC 27.510. UNIFORM STANDARDS. (a) The screening of newborn children for metabolic disorders under 7 AAC 27.510 - 7 AAC 27.580 must be performed at a single laboratory designated by the department. The screening must be performed on a specimen of the newborn child’s blood collected as specified in 7 AAC 27.530. The screening must include tests for phenylketonuria, hypothyroidism, galactosemia, and congenital adrenal hyperplasia. Other conditions may be tested for if the designated laboratory has a test method suitable to the department.

(b) Unless the parent or guardian denies a request for specimens as described in AS 18.15.200(f), screening under 7 AAC 27.510 - 7 AAC 27.580 is required for a newborn child in the state. A newborn child who has not been screened must be reported to the department as prescribed in 7 AAC 27.530(c) and (d). (Eff. 12/30/77, Register 64; am 2/3/88, Register 105; am 7/13/94, Register 131)

Authority: AS 18.05.040
AS 18.15.200

7 AAC 27.520. PERSONS REQUIRED TO COLLECT SPECIMENS. (a) Responsibility for collection and submission of specimens resides with the physician or certified nurse midwife under AS 18.15.200, or certified direct entry midwife under 12 AAC 14.530 attending the newborn child. A newborn child who is not attended by one of these health care providers should be presented by the child’s parent or guardian as early as possible within the newborn child’s first six weeks to a physician or public health nurse for the required testing as described in 7 AAC 27.530.

(b) If a newborn child is receiving care in a medical facility or is admitted to a medical facility within 48 hours of age, the blood specimen required in 7 AAC 27.510 must be collected before that child’s discharge or transfer to another medical facility. (Eff. 12/30/77, Register 64; am 2/3/88, Register 105; am 7/13/94, Register 131)

Authority: AS 18.05.040
AS 18.15.200

7 AAC 27.530. COLLECTION OF BLOOD SPECIMEN; REFUSAL OF COLLECTION. (a) The minimum blood specimen collection requirements for the screening described in 7 AAC 27.510 are

1. one specimen if
   (A) the newborn child was born full term, had a normal birthweight and is living; the specimen is to be collected between 48 hours and seven days of age of the child; or
   (B) the child was born alive, but died before the child reached 48 hours of age, and a post mortem blood specimen can be obtained; or

2. two specimens if
   (A) the newborn child was born prematurely, had a low birth weight, and is living; the first specimen must be collected between 48 hours and seven days of age of the child and the second specimen must be collected before 21 days of age of the child; or
(B) the initial specimen was collected before the newborn child was 48 hours of age; the second specimen must be collected after 72 hours of age of the child but before 21 days of age of the child; or
(C) the screening of the initial specimen has shown a borderline result for one or more of the tested conditions or the specimen was contaminated, spoiled, or otherwise not adequate for screening.

(b) The blood specimen must be collected using the procedure described on the test form for the screening provided by the department. The specimen must be submitted on the absorbent card provided by the department. All information requested on the test form must be provided by the attending physician, certified nurse midwife, or certified direct entry midwife. The specimen must be mailed with the required form to a designated laboratory within 24 hours of the time the specimen is collected.

(c) Each week a medical facility or service shall provide a list of live births to the section of maternal, adolescent and genetics unit in the department, a list of live births. The list must contain the newborn child’s surname or family name, date of birth, birth weight, and sex. If a newborn child is not tested for any reason, including the denial of specimen collection by a parent or guardian, the nontesting of that child must also be noted on the list. The department will match the list of live births against the designated laboratory’s list of specimens received. The department will notify the medical facility or service regarding a newborn child whose blood specimen was reported collected, but had not been received by the designated laboratory.

(d) A parent or guardian of a newborn child who refuses to permit collection of a specimen should affirm that refusal by signing the “refusal for testing statement” on the back of the newborn child screening card provided by the department. The information on the front of the card must be completed by the medical facility or service, and the card sent to the designated laboratory. (Eff. 12/30/77, Register 64; am 10/31/82, Register 84; am 2/3/88, Register 105; am 7/13/94, Register 131)

Authority:  AS 18.05.040
            AS 18.15.200

Editor’s notes: The address for the Department of Health and Social Services, Division of Health Care Services, is 3601 C Steet, Ste. 934, Anchorage, Alaska 99524.

7 AAC 27.540. SPECIMEN COLLECTION MATERIALS. The department will, upon request, provide a physician, certified nurse midwife, or certified direct entry midwife with specimen collection materials, test forms, and mailing containers at no charge. A request for these materials, forms and containers must be directed to the maternal, adolescent and genetics unit in the department. (Eff. 12/30/77, Register 64; am 10/31/82, Register 84; am 12/6/86, Register 100; am 2/3/88, Register 105; am 7/13/94, Register 131)

Authority:  AS 18.05.040
            AS 18.15.200

Editor’s Notes: The address for the Department of Health and Social Services, Division of Health Care Services, is 3601 C Steet, Ste. 934, Anchorage, Alaska 99524.

7 AAC 27.550. RESULTS OF SCREENING TEST. (a) Screening test results must be returned to the physician, certified nurse midwife, or certified direct entry midwife as indicated on the return address portion of the screening test form.
(b) Screening test results must indicate whether the specimen was negative, positive, or in any way abnormal, for each test performed. If a borderline positive initial screening test result is followed by a second screening test result that is normal, the test result must be classified as a normal screening result.

(c) The designated laboratory shall report to the health care provider by telephone any positive or abnormal results requiring action. This same information must be reported to the department by telephone. Normal results must be reported by mail to the health care provider described in (a) of this section within 30 days. (Eff. 12/30/77, Register 64; am 2/3/88, Register 105; am 7/13/94, Register 131)

Authority: AS 18.05.040
AS 18.15.200

Editor’s Notes: The address for the Department of Health and Social Services, Division of Health Care Services, is 3601 C Steet, Ste. 934, Anchorage, Alaska 99524.

7 AAC 27.560. CONFIRMATION. (a) Diagnostic confirmatory testing must be conducted on a newborn child with abnormal screening test results after two screening specimens have been processed. A newborn child with an abnormal result shall be referred to a physician for the diagnostic confirmatory testing by the practitioner who ordered the screening test under 7 AAC 27.530.

(b) A blood specimen must be obtained for the diagnostic confirmatory testing. The diagnostic confirmatory testing of the specimen sent to the designated laboratory must be performed at no charge to the family or physician. The physician may choose to use a diagnostic laboratory other than the designated laboratory for diagnostic confirmatory testing of the specimen. The department will not pay for costs incurred by use of a nondesignated laboratory for the testing.

(c) If diagnostic confirmatory testing is done through a laboratory other than a designated laboratory, the physician shall report, in writing, the results of the diagnostic confirmatory testing to the maternal, adolescent and genetics unit in the department, within 30 days after the date of receipt of results of the abnormal specimen.

(d) When a newborn child has an abnormal screening test result and a diagnostic confirmatory report is not received by the department from the designated laboratory, the department will contact the child’s health care provider.

(e) The department will provide the child’s health care provider with consultation with an appropriate medical specialist for a newborn child with a confirmed diagnosis of a disabling, or potentially disabling, metabolic disorder. (Eff. 12/30/77, Register 64; am 2/3/88, Register 105; am 7/13/94, Register 131)

Authority: AS 18.05.040
AS 18.15.200

Editor’s Notes: The address for the Department of Health and Social Services, Division of Health Care Services, is 3601 C Steet, Ste. 934, Anchorage, Alaska 99524.

7 AAC 27.570. ANNUAL REVIEW AND REPORT. The department will appoint a committee to annually review the results of the newborn child metabolic disorder screening program, consider addition or deletion of tests based on experience in this state and on newly developed tests recommended by the American Academy of Pediatrics, Committee on Genetics, and report to health care providers and the public on these matters. (Eff. 2/3/88, Reg. 105; am 7/13/94, Register 131)
Authority: AS 18.05.040  
AS 18.15.200

Editor's notes. - Information on newly developed metabolic screening tests recommended by the American Academy of Pediatrics may be obtained by contacting the American Academy of Pediatrics, 141 Northwest Point Blvd., P.O. Box 927, Elk Grove Village, Illinois 60069-0927.

7 AAC 27.575. CONFIDENTIALITY. Information obtained from testing under 7 AAC 27.010 - 7 AAC 27.580 is a confidential medical public health record and is exempt from inspection under AS 09.25.120. A person who or a facility that produces, uses or compiles this information must maintain procedures to protect this information from loss, tampering, or access by an unauthorized person. (Eff. 7/13/94, Register 131)

Authority: AS 09.25.120  
AS 18.05.040  
AS 18.15.200

7 AAC 27.580. REPORTING NON-COMPLIANCE. If the department has information that leads it to believe that a hospital, birthing center, home birth service, physician, certified nurse midwife, or certified direct entry midwife is not complying with 7 AAC 27.510 - 7 AAC 27.570 or 12 AAC 14.530, the department will report the information to appropriate state officials and to the appropriate licensing or accreditation agency. (Eff. 2/3/88, Register 105; am 7/13/94, Register 131)

Authority: AS 18.05.040  
AS 18.15.200

7 AAC 27.590. DEFINITIONS. In 7 AAC 27.510 - 7 AAC 27.590

(1) “designated laboratory” means a laboratory designated by the department to perform screening of blood specimens for metabolic disorders;

(2) “department” means the Department of Health and Social Services; and

(3) “medical facility or service” means a hospital, birthing center, or home birthing service.

(Eff. 7/13/94, Register 131)

Authority: AS 18.05.040  
AS 18.15.200